Publications: Prof Peter Schmid

Dent RA, Hui R, Park YH, Schmid P, Wei J, Mejia JA, Pan W, Cortés J et al. ( 2024 ) . 24TiP A phase III, randomized study of adjuvant sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs treatment of physician’s choice (TPC) in patients with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery . Annals of Oncology vol. 35 ,

Turner NC, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S et al. ( 2024 ) . Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer . New England Journal of Medicine vol. 391 , ( 17 ) 1584 - 1596 .

Teng NM, Malfettone A, Dalby MJ, Kiu R, Seki D, Robinson T, Gion M, Bermejo B et al. ( 2024 ) . Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin . Microbiome Research Reports vol. 3 , ( 4 ) n/a - n/a .

Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, Carter S et al. ( 2024 ) . A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study . Clinical Cancer Research vol. 30 , ( 23 ) 5304 - 5313 .

Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E et al. ( 2024 ) . PS3-2 Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2− metastatic breast cancer . Annals of Oncology vol. 35 , s1314 - s1315 .

Quintana A, Saini KS, Vidal L, Peg V, Slebe F, Loibl S, Curigliano G, Schmid P et al. ( 2024 ) . Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer . ESMO Open vol. 9 , ( 10 )

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH et al. ( 2024 ) . Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer . New England Journal of Medicine vol. 391 , ( 21 ) 1981 - 1991 .

Im S-A, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, Takano T, Huang C-S et al. ( 2024 ) . Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC . npj Breast Cancer vol. 10 , ( 1 )

Jhaveri KL, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K et al. ( 2024 ) . Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer . Journal of Clinical Oncology vol. 42 , ( 33 ) 3947 - 3956 .

Rugo HS, Zhang Y, Marmé F, Schmid P, Cortés J, Tolaney SM, Tang S, Yoon OK et al. ( 2024 ) . 412P Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02 . Annals of Oncology vol. 35 , s391 - s392 .

O'Shaughnessy J, Cortés J, Schmid P, Xu B, Shao Z, Teixeira L, Sendur MAN, Sabanathan D et al. ( 2024 ) . 436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer . Annals of Oncology vol. 35 ,

Schmid P, McArthur HL, Cortés J, Xu B, Cardoso F, Casalnuovo ML, Demirci U, Freitas R et al. ( 2024 ) . LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial . Annals of Oncology vol. 35 , s1212 - s1213 .

Schmid P, Cortés J, Dent RA, McArthur HL, Pusztai L, Kummel S, Denkert C, Park YH et al. ( 2024 ) . LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study . Annals of Oncology vol. 35 , s1204 - s1205 .

Sohn J, Pistilli B, Bellet M, Del Mastro L, McArthur HL, Meisel JL, Schmid P, Wei R et al. ( 2024 ) . OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors . Journal of Clinical Oncology vol. 42 , ( 23_suppl ) tps22 - tps22 .

Anders C, Loi S, Hamilton E, Jhaveri K, Schmid P, Gökmen E, Im S-A, Karaçin C et al. ( 2024 ) . NVTG-07 SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC) AND ACTIVE BRAIN METASTASES (BMS) IN DESTINY-BREAST07 (DB-07) . Neuro-Oncology Advances vol. 6 , ( Supplement_1 ) i25 - i25 .

Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, Paré L, Villacampa G, Gion M, Schmid P, Colleoni M et al. ( 2024 ) . HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial . Clinical Cancer Research vol. 30 , ( 18 ) of1 - of8 .

Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al. ( 2024 ) . Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study . Journal of the National Cancer Institute vol. 116 , ( 10 ) 1654 - 1663 .

Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil MJG, Ruiz-Borrego M, Gavilá J, Aguirre E et al. ( 2024 ) . Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer . The Breast vol. 76 ,

Conte PF, Dieci MV, Bisagni G, Schmid P, Fotia V, Piacentini F, De Laurentiis M, Favaretto AG et al. ( 2024 ) . A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy . Journal of Clinical Oncology vol. 42 , ( 17_suppl ) lba500 - lba500 .

Andre F, Hamilton EP, Loi S, Anders CK, Schmid P, Stroyakovskiy D, Villanueva R, Pedrini JL et al. ( 2024 ) . DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 1009 - 1009 .

Giordano A, Sharma M, Williams A, Schmid P, Flores Diaz DF, Magallanes M, Xu B, Yan M et al. ( 2024 ) . First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 3108 - 3108 .

Juric D, Kalinsky K, Turner NC, Jhaveri KL, Schmid P, Loi S, Saura C, Im S-A et al. ( 2024 ) . First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 1003 - 1003 .

Bardia A, Zhang Y, Marmé F, Schmid P, Cortes J, Tolaney SM, Zhang Y, Yoon OK et al. ( 2024 ) . Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 1075 - 1075 .

Juric D, Kalinsky K, Im S-A, Ciruelos E, Bianchini G, Barrios CH, Jacot W, Schmid P et al. ( 2024 ) . INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps1136 - tps1136 .

Graeser MK, Gluz O, Schmid P, Jozwiak K, Feuerhake F, Volk V, Ulbrich-Gebauer D, Biehl C et al. ( 2024 ) . Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 590 - 590 .

Harbeck N, Braun M, Gluz O, Schmid P, Graeser MK, Hartkopf AD, Hoffmann O, Kostara A et al. ( 2024 ) . Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps631 - tps631 .

Pistilli B, Bellet M, Del Mastro L, McArthur HL, Meisel JL, Schmid P, Sohn J, De Kermadec E et al. ( 2024 ) . OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps1135 - tps1135 .

Rugo HS, Tolaney SM, Bardia A, Cortes J, Marmé F, Schmid P, Carey LA, Loibl S et al. ( 2024 ) . Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 3029 - 3029 .

Licata L, Dieci MV, De Angelis C, Marchiò C, Miglietta F, Cortesi L, Fabi A, Schmid P et al. ( 2024 ) . Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer . Cancer Treatment Reviews vol. 128 ,

Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A et al. ( 2024 ) . Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial . The Oncologist vol. 29 , ( 9 ) 768 - 779 .

Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM et al. ( 2024 ) . IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer . Annals of Oncology vol. 35 , ( 7 ) 630 - 642 .

Hamann M, Gluz O, Christgen M, Nitz U, Kuemmel S, Braun M, Thill M, Wuerstlein R et al. ( 2024 ) . Endocrine response assessment by Ki67: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial . Senologie - Zeitschrift für Mammadiagnostik und -therapie vol. 21 , ( 02 ) e11 - e12 .

Cardoso F, O'Shaughnessy J, McArthur H, Schmid P, Cortés J, Harbeck N, Telli M, Cescon D et al. ( 2024 ) . Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756 . Cancer Research vol. 84 , ( 9_Supplement )

Jhaveri KL, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S et al. ( 2024 ) . Abstract GS03-13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis . Cancer Research vol. 84 , ( 9_Supplement )

Schmid P, Cortés J, Dent R, Pusztai L, McArthur H, Küemmel S, Denkert C, Park YH et al. ( 2024 ) . Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study . Cancer Research vol. 84 , ( 9_Supplement )

Gluz O, Christgen M, Nitz U, Küemmel S, Braun M, Thill M, Wuerstlein R, Wimberger P et al. ( 2024 ) . Abstract LBO1-05: Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334) . Cancer Research vol. 84 , ( 9_Supplement )

Graeser M, Kuemmel S, Gluz O, Schroeder C, Schuetz L, Kelemen O, Ossowski S, Jozwiak K et al. ( 2024 ) . Abstract PO1-15-12: Circulating tumor DNA (ctDNA) for prediction of pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial . Cancer Research vol. 84 , ( 9_Supplement )

Schmid P, Ma C, Huisden R, Stewart R, Heider K, Vuković P, Denduluri N ( 2024 ) . Abstract PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study . Cancer Research vol. 84 , ( 9_Supplement )

Llombart-Cussac A, Pérez-García JM, Gion M, Alcalá-López D, Fazal-Salom J, Lazaris A, Mancino M, Shimizu E et al. ( 2024 ) . Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC) . Cancer Research vol. 84 , ( 9_Supplement )

McArthur H, Tolaney S, Loibl S, Dent R, Schmid P, Asselah J, Song E, Niikura N ( 2024 ) . Abstract PO1-20-13: TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2– breast cancer . Cancer Research vol. 84 , ( 9_Supplement )

Brasó-Maristany F, Cortés J, Pérez-García JM, Vega-León R, Paré L, Villacampa G, Matito J, Pardo F et al. ( 2024 ) . Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial . Cancer Research vol. 84 , ( 9_Supplement )

Juric D, Kalinsky K, Im S-A, Ciruelos E, Bianchini G, Barrios C, Jacot W, Schmid P et al. ( 2024 ) . Abstract PO2-19-08: INAVO121: Phase III study of inavolisib + fulvestrant vs alpelisib + fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer . Cancer Research vol. 84 , ( 9_Supplement )

Gluz O, Christgen M, Nitz U, Küemmel S, Braun M, Thill M, Wuerstlein R, Wimberger P et al. ( 2024 ) . Abstract PO3-18-10: Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter WSG-ADAPTcycle trial (n=5,290) . Cancer Research vol. 84 , ( 9_Supplement )

Schmid P, Bachelot T, Bianchini G, Harbeck N, Loi S, Park Y, Prat A, Gilham L et al. ( 2024 ) . Abstract PO3-20-01: ASTEFANIA: a Phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy . Cancer Research vol. 84 , ( 9_Supplement )

Bardia A, Schmid P, Tolaney S, Marmé F, Cortés J, Valdez T, Wang H, Verret W et al. ( 2024 ) . Abstract PO5-21-09: Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2‒ metastatic breast cancer . Cancer Research vol. 84 , ( 9_Supplement )

Graeser M, Gluz O, Eulenburg CZ, Küemmel S, von Schumann R, Christgen M, Wuerstlein R, Pelz E et al. ( 2024 ) . Abstract PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group . Cancer Research vol. 84 , ( 9_Supplement )

Cortés J, Dent R, Pusztai L, McArthur H, Kuemmel S, Denkert C, Park YH, Hui R et al. ( 2024 ) . Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC) . Cancer Research vol. 84 , ( 9_Supplement )

Rugo H, Schmid P, Nowecki Z, Cescon D, Im S-A, Yusof M, Gallardo C, Iwata H et al. ( 2024 ) . Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer . Cancer Research vol. 84 , ( 9_Supplement )

Burrell R, Kumar S, McIntosh S, Pitsinis V, King P, Elsberger B, Govindarajulu S, Satherley L et al. ( 2024 ) . Abstract PS15-06: Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction . Cancer Research vol. 84 , ( 9_Supplement )

Llombart-Cussac A, Pérez-García JM, Ezquerra MB, Dalenc F, Gil-Gil M, Ruíz - Borrego M, Gavilá J, Schmid P et al. ( 2024 ) . Abstract RF01-03: PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study . Cancer Research vol. 84 , ( 9_Supplement )

Jhaveri K, André F, Hamilton E, Schmid P, Anders C, Testa L, Ganshina I, Lu Y-S et al. ( 2024 ) . Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08) . Cancer Research vol. 84 , ( 9_Supplement )

Loibl S, Tolaney SM, Schmid P, Pistilli B, Dent RA, Asselah J, Liu Q, Meisel JL et al. ( 2024 ) . 159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC) . ESMO Open vol. 9 ,

Dent RA, André F, Gonçalves A, Jimenez MM, Schmid P, Schütz F, Kummel S, Swain SM et al. ( 2024 ) . 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC) . ESMO Open vol. 9 ,

Schmid P, Loi S, De la Cruz Merino L, Yerushalmi R, Im S-A, Sonnenblick A, Garcia MM, Candilejo IM et al. ( 2024 ) . 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) . ESMO Open vol. 9 ,

Anders C, Loi S, Hamilton EP, Jhaveri K, Schmid P, Gokmen E, Im S-A, Karacin C et al. ( 2024 ) . 185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07) . ESMO Open vol. 9 ,

Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im S-A, Loi S, Saji S et al. ( 2024 ) . 261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . ESMO Open vol. 9 ,

Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, Okines A, Chopra N et al. ( 2024 ) . Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom . British Journal of Cancer vol. 130 , ( 12 ) 1916 - 1920 .

Cortes J, Winer EP, Lipatov O, Im S, Gonçalves A, Muñoz‐Couselo E, Lee KS, Schmid P et al. ( 2024 ) . Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119 . The Journal of Pathology Clinical Research vol. 10 , ( 3 )

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Spears PA, Tolaney SM ( 2024 ) . A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative) . Future Oncology vol. 20 , ( 11 ) 635 - 651 .

Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S et al. ( 2024 ) . Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial . Journal of Nuclear Medicine vol. 65 , ( 5 )

Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S et al. ( 2024 ) . 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial . The Lancet vol. 403 , ( 10437 ) 1649 - 1659 .

Cardoso F, O’Shaughnessy J, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW et al. ( 2024 ) . 4 Oral Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study . European Journal of Cancer vol. 200 ,

Pusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J et al. ( 2024 ) . Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522☆ . Annals of Oncology vol. 35 , ( 5 ) 429 - 436 .

Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim S-B, Sablin M-P, Saji S, Savas P et al. ( 2024 ) . First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results . Clinical Cancer Research vol. 30 , ( 4 ) 767 - 778 .

Cescon DW, Schmid P, Rugo HS, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH et al. ( 2023 ) . Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 . Journal of the National Cancer Institute vol. 116 , ( 5 ) 717 - 727 .

Takahashi M, Cortés J, Dent R, Pusztai L, McArthur H, Kümmel S, Denkert C, Park YH et al. ( 2023 ) . Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer . JAMA Network Open vol. 6 , ( 11 )

Heong VYM, Marmé F, Rugo HS, Tolaney SM, Bardia A, Schmid P, Verret W, Valdez T et al. ( 2023 ) . 54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) . Annals of Oncology vol. 34 , s1486 - s1487 .

Park YH, Im S-A, Ahn J-H, Kim MH, Cortés J, Dent RA, Pusztai L, McArthur HL et al. ( 2023 ) . LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis . Annals of Oncology vol. 34 , s1467 - s1468 .

Schmid P, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Tamura K, Testa L et al. ( 2023 ) . Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study . European Journal of Cancer vol. 195 ,

Cussac AL, Pérez-García JM, Brunet LP, Javierre GV, Brasó-Maristany F, Cortes MG, Schmid P, Colleoni MA et al. ( 2023 ) . 150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial . Annals of Oncology vol. 34 , s240 - s241 .

Angelis V, Scott E, Gousis C, Hall PE, Hawkesford KM, Nijjar R, Nathan M, Schmid P et al. ( 2023 ) . 253P Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK . Annals of Oncology vol. 34 ,

Schmid P, Wysocki PJ, Ma CX, Park YH, Fernandes R, Lord S, Baird RD, Prady C et al. ( 2023 ) . 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study . Annals of Oncology vol. 34 ,

Schmid P, Cortés J, Dent RA, Pusztai L, McArthur HL, Kummel S, Denkert C, Park YH et al. ( 2023 ) . LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study . Annals of Oncology vol. 34 ,

Cardoso F, McArthur HL, Schmid P, Cortés J, Harbeck N, Telli ML, Cescon DW, O'Shaughnessy J et al. ( 2023 ) . LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer . Annals of Oncology vol. 34 , s1260 - s1261 .

Cortes J, Haiderali A, Huang M, Pan W, Schmid P, Akers KG, Park JE, Frederickson AM et al. ( 2023 ) . Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis . BMC Cancer vol. 23 , ( 1 )

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E et al. ( 2023 ) . Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial . The Lancet vol. 402 , ( 10411 ) 1423 - 1433 .

Loibl S, Azim HA, Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ et al. ( 2023 ) . ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) . Annals of Oncology vol. 34 , ( 10 ) 849 - 866 .

Dent RA, Cescon DW, Bachelot T, Jung KH, Shao Z-M, Saji S, Traina TA, Vukovic P et al. ( 2023 ) . TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer . Future Oncology vol. 19 , ( 35 ) 2349 - 2359 .

Fasching PA, Neven P, Stahl N, Vidal M, Martin M, Harbeck N, Kaufman PA, Bidard F-C et al. ( 2023 ) . A Preoperative Window-of-Opportunity Study of Imlunestrant in Estrogen Receptor-positive, HER2-negative Early Breast Cancer: Results from the EMBER-2 Study . Senologie - Zeitschrift für Mammadiagnostik und -therapie . Conference: 42. Jahreskongress der Deutschen Gesellschaft für Senologie e.V. (DGS) vol. 20 , e2 - e3 .

Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P et al. ( 2023 ) . XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease . Breast Cancer Research vol. 25 , ( 1 )

Cortes J, Pérez-García JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N et al. ( 2023 ) . 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) . Journal of Clinical Oncology vol. 41 , ( 17_suppl ) lba506 - lba506 .

Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ et al. ( 2023 ) . ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer . Annals of Oncology vol. 34 , ( 8 ) 645 - 659 .

Tolaney SM, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Tredan O, Ciruelos EM et al. ( 2023 ) . Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 1003 - 1003 .

Juric D, Kalinsky K, Im S-A, Ciruelos EM, Bianchini G, Barrios CH, Jacot W, Schmid P et al. ( 2023 ) . INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) tps1123 - tps1123 .

Bardia A, Rugo HS, Cortés J, Tolaney SM, Schmid P, Motwani M, Yoon OK, Boice J et al. ( 2023 ) . Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 1082 - 1082 .

Geyer C, Bardia A, Harbeck N, Rimawi MF, Hurvitz SA, Martin M, Loi S, Saji S et al. ( 2023 ) . lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) tps616 - tps616 .

Azevedo F, Pavlović T, Rêgo GG, Ay FC, Gjoneska B, Etienne TW, Ross RM, Schönegger P et al. ( 2023 ) . Social and moral psychology of COVID-19 across 69 countries . Scientific Data vol. 10 , ( 1 )

Quintana Á, Arenas EJ, Bernadó C, Navarro JF, González J, Esteve-Codina A, Moliné T, Marti M et al. ( 2023 ) . Evaluation of triple negative breast cancer with heterogeneous immune infiltration . Frontiers in Immunology vol. 14 ,

Cortés J, Lipatov O, Im S-A, Gonçalves A, Lee KS, Schmid P, Tamura K, Testa L et al. ( 2023 ) . 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119 . ESMO Open vol. 8 , ( 1 )

Cameron DAA, Jacot W, Yamashita T, Losada MJV, Schmid P, Lee KS, De Laurentiis M, Zagouri F et al. ( 2023 ) . 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC) . ESMO Open vol. 8 , ( 1 )

Hanna D, Merrick S, Ghose A, Yang D, Phillips E, Chopra NR, Ross K, Boh ZY et al. ( 2023 ) . 232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom . ESMO Open vol. 8 , ( 1 )

Loi S, Salgado R, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2023 ) . Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis . JCO Precision Oncology vol. 7 , ( 7 )

Reinisch M, Bruzas S, Gluz O, Ataseven B, Schmid P, Cortés J, Blohmer J, Shenoy S et al. ( 2023 ) . Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy . Molecular Oncology vol. 17 , ( 6 ) 1060 - 1075 .

Rudin CM, Cervantes A, Dowlati A, Besse B, Ma B, Costa DB, Schmid P, Heist R et al. ( 2023 ) . Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer . ESMO Open vol. 8 , ( 2 )

Oswald AJ, Symeonides SN, Wheatley D, Chan S, Brunt AM, McAdam K, Schmid P, Waters S et al. ( 2023 ) . Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study . Breast Cancer Research and Treatment vol. 199 , ( 1 ) 35 - 46 .

Rugo H, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E et al. ( 2023 ) . Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) . Cancer Research vol. 83 , ( 5_Supplement )

Turner N, Phillips ER, Bunce C, Robert M, Bailleux C, Garcia-Murillas I, Khabra K, Macpherson I et al. ( 2023 ) . Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER) . Cancer Research vol. 83 , ( 5_Supplement )

Dent R, Cescon DW, Bachelot T, Jung KH, Shao Z-M, Saji S, Traina TA, Vuković P et al. ( 2023 ) . Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy . Cancer Research vol. 83 , ( 5_Supplement )

Schmid P, Geyer Jr CE, Harbeck N, Rimawi M, Hurvitz S, Martín M, Loi S, Saji S et al. ( 2023 ) . Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer . Cancer Research vol. 83 , ( 5_Supplement )

Tolaney S, Schmid P, Bardia A, Marmé F, Loirat D, Sharma P, Wang H, Fu O et al. ( 2023 ) . Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC) . Cancer Research vol. 83 , ( 5_Supplement )

Marmé F, Bardia A, Rugo H, Schmid P, Tolaney SM, Oliveira M, Schneeweiss A, Shi L et al. ( 2023 ) . Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial . Cancer Research vol. 83 , ( 5_Supplement )

Graeser M, Kuemmel S, Gluz O, Feuerhake F, Volk V, Ulbrich-Gebauer D, Biehl C, Reinisch M et al. ( 2023 ) . Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial . Cancer Research vol. 83 , ( 5_Supplement )

Neven P, Stahl N, Vidal M, Martín M, Harbeck N, Kaufman PA, Bidard F-C, Fasching PA et al. ( 2023 ) . Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study . Cancer Research vol. 83 , ( 5_Supplement )

Chibly AM, Shia A, Johnson R, Hwang MS, Hafner M, Metcalfe C, Shah K, Slyper M et al. ( 2023 ) . Abstract PD10-06: PD10-06 Clinical outcomes and exploratory gene expression analysis of OPPORTUNE: a phase II window-of-opportunity study to evaluate pictilisib+anastrozole versus anastrozole alone in ER-positive breast cancer . Cancer Research vol. 83 , ( 5_Supplement )

Schmid P, Wysocki P, Park YH, Jassem J, Jung KH, Lord S, Huisden R, Stewart R et al. ( 2023 ) . Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study . Cancer Research vol. 83 , ( 5_Supplement )

Schmid P, Wysocki P, Ma C, Park YH, Fernandes R, Lord S, Baird RD, Prady C et al. ( 2023 ) . Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study . Cancer Research vol. 83 , ( 5_Supplement )

Cosimo SD, Pérez-García JM, Ezquerra MB, Dalenc F, Gil MG, Borrego MR, Gavilá J, Sampayo-Cordero M et al. ( 2023 ) . Abstract PD13-10: PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2- ABC): Exploratory Analysis of the PARSIFAL Trial . Cancer Research vol. 83 , ( 5_Supplement )

Hamilton E, Jhaveri K, Loi S, Anders C, Schmid P, Penkov K, Artamonova E, Zhukova L et al. ( 2023 ) . Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) . Cancer Research vol. 83 , ( 5_Supplement )

McArthur H, Cortés J, Dent R, O’Shaughnessy J, Pusztai L, Küemmel S, Foukakis T, Park YH et al. ( 2023 ) . Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study . Cancer Research vol. 83 , ( 5_Supplement )

Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter‐Riniker F, Günthard HF, Rockstroh JK et al. ( 2023 ) . Hepatitis delta infection among persons living with HIV in Europe . Liver International vol. 43 , ( 4 ) 819 - 828 .

Cortes J, Perez-Garcia JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Martinez LC, Ribelles N et al. ( 2023 ) . 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Tolaney SM, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos EM et al. ( 2023 ) . Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Juric D, Kalinsky K, Im S-A, Ciruelos EM, Bianchini G, Barrios CH, Jacot W, Schmid P et al. ( 2023 ) . INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Kuemmel S, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau J-F, Cortes J, McArthur H et al. ( 2023 ) . Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study . ANNALS OF SURGICAL ONCOLOGY . vol. 30 , S295 - S296 .

Kuemmel S, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau J-F, Cortes J, McArthur H et al. ( 2023 ) . Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study . BREAST . vol. 68 , S63 - S64 .

Bardia A, Rugo HS, Cortes J, Tolaney SM, Schmid P, Motwani M, Yoon OK, Boice J et al. ( 2023 ) . Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2-metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Geyer C, Bardia A, Harbeck N, Rimawi MF, Hurvitz SA, Martin M, Loi S, Saji S et al. ( 2023 ) . lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K et al. ( 2022 ) . Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer . Annals of Oncology vol. 34 , ( 2 ) 200 - 211 .

Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L et al. ( 2022 ) . ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer . Future Oncology vol. 18 , ( 32 ) 3563 - 3572 .

Pérez-García JM, Gebhart G, Borrego MR, Schmid P, Marmé F, Prat A, Dalenc F, Kerrou K et al. ( 2022 ) . Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study . Future Oncology vol. 18 , ( 33 ) 3677 - 3688 .

Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M et al. ( 2022 ) . Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial . The Oncologist vol. 28 , ( 1 ) 23 - 32 .

Sun R, Wei L-J ( 2022 ) . Pembrolizumab in Triple-Negative Breast Cancer . New England Journal of Medicine vol. 387 , ( 15 ) 1435 - 1436 .

de Castro G, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V et al. ( 2022 ) . NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC . Journal of Thoracic Oncology vol. 18 , ( 1 ) 106 - 119 .

Dent RA, Cortés J, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C, Park YH et al. ( 2022 ) . 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 . Annals of Oncology vol. 33 , s600 - s601 .

Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Gharaibeh M et al. ( 2022 ) . 1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) . Annals of Oncology vol. 33 ,

Schmid P, Cortés J, Marmé F, Rugo HS, Tolaney SM, Oliveira M, Loirat D, Jhaveri K et al. ( 2022 ) . 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study . Annals of Oncology vol. 33 , s635 - s636 .

Tolaney SM, de Azambuja E, Emens LA, Loi S, Pan W, Huang J, Sun SW, Lai C et al. ( 2022 ) . 276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC) . Annals of Oncology . vol. 33 , s664 - s665 .

Gluz O, Nitz UA, Christgen M, Kuemmel S, Braun M, Thill M, Aktas B, Wimberger P et al. ( 2022 ) . LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials . Annals of Oncology vol. 33 , s1382 - s1383 .

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Tredan O, Ciruelos EM et al. ( 2022 ) . LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) . Annals of Oncology vol. 33 ,

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E et al. ( 2022 ) . Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer . Journal of Clinical Oncology vol. 40 , ( 29 ) 3365 - 3376 .

Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH et al. ( 2022 ) . Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer . New England Journal of Medicine vol. 387 , ( 3 ) 217 - 226 .

Takano T, Cortes J, Cescon DW, Im S-A, Yusof MM, Iwata H, Masuda N, Huang C-S et al. ( 2022 ) . PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer . Annals of Oncology vol. 33 ,

Takahashi M, Cortés J, Dent R, Pusztai L, Mcarthur H, Kümmel S, Denkert C, Park YH et al. ( 2022 ) . PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup . Annals of Oncology vol. 33 ,

Kim D-W, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A et al. ( 2022 ) . Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC . JTO Clinical and Research Reports vol. 3 , ( 8 )

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E et al. ( 2022 ) . Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer . Journal of Clinical Oncology vol. 40 , ( 17_suppl ) lba1001 - lba1001 .

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT et al. ( 2022 ) . Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer . New England Journal of Medicine vol. 387 , ( 1 ) 9 - 20 .

Rogerson S, Turner H, Bilkhu A, Monturus E, Knott A, Restuccia E, Quashie N, Wheatley D et al. ( 2022 ) . Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) e12504 - e12504 .

Andre F, Hamilton EP, Loi S, Im S-A, Sohn J, Tseng L-M, Anders CK, Schmid P et al. ( 2022 ) . Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 3025 - 3025 .

De Laurentiis M, Costa L, Gligorov J, Knop A, Senkus-Konefka E, García-Sáenz JA, Schmid P, Heniquez A et al. ( 2022 ) . EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) tps1109 - tps1109 .

Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent RA, McArthur HL, Kuemmel S, Bergh JCS et al. ( 2022 ) . Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522 . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 503 - 503 .

Molinero L, Guan X, Deurloo R, Gozlan Y, Sharim H, Emens LA, Cameron DA, Schmid P et al. ( 2022 ) . Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 1083 - 1083 .

Rugo HS, Sohn J, Gilarranz YJ, Gonzalez-Cortijo L, Sonnenblick A, Sabanathan D, Korbenfeld EP, Egle D et al. ( 2022 ) . KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) tps1118 - tps1118 .

Molinero L, Emens LA, Goldstein LD, Abbas AR, Koeppen H, Rugo HS, Adams S, Chui SY et al. ( 2022 ) . Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 1078 - 1078 .

Cortes M, Salgado AC, Murillo SM, Blancas I, Cortez P, Plaza IC, Fernandez ND, Martinez-Bueno A et al. ( 2022 ) . Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 1084 - 1084 .

Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J et al. ( 2022 ) . A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer . Nature Cancer vol. 3 , ( 6 ) 696 - 709 .

Ganguly S, Gogia A ( 2022 ) . Pembrolizumab in Early Triple-Negative Breast Cancer . New England Journal of Medicine vol. 386 , ( 18 )

Teng N, Dalby MJ, Kiu R, Robinson T, Cortes MG, De Las Heras BB, Garcia JMP, Calvo-Martinez L et al. ( 2022 ) . 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO . Annals of Oncology vol. 33 , s129 - s130 .

Cescon DW, Schmid P, Rugo HS, Im S-A, Yusof MM, Gallardo CE, Lipatov O, Barrios CH et al. ( 2022 ) . 164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355 . Annals of Oncology . vol. 33 , s197 - s198 .

Schmid P, Jung KH, Wysocki PJ, Jassem J, Ma CX, Fernandes R, Huisden R, Stewart R et al. ( 2022 ) . 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study . Annals of Oncology vol. 33 ,

Salgado AC, Garcia JMP, Castedo SPC, Cortes MG, Murillo SM, López-Barajas IB, Blanch S, Plaza IC et al. ( 2022 ) . 205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC) . Annals of Oncology vol. 33 ,

Van Bavel JJ, Cichocka A, Capraro V, Sjåstad H, Nezlek JB, Pavlović T, Alfano M, Gelfand MJ et al. ( 2022 ) . Author Correction: National identity predicts public health support during a global pandemic . Nature Communications vol. 13 , ( 1 )

Bruzas S, Gluz O, Harbeck N, Schmid P, Cortés J, Blohmer J, Seiberling C, Chiari O et al. ( 2022 ) . Gene signatures in patients with early breast cancer and relapse despite pathologic complete response . npj Breast Cancer vol. 8 , ( 1 )

Hall PE, Schmid P ( 2022 ) . Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies . Breast Cancer Research and Treatment vol. 193 , ( 1 ) 21 - 35 .

Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G et al. ( 2022 ) . Immunotherapy for early triple negative breast cancer: research agenda for the next decade . npj Breast Cancer vol. 8 , ( 1 )

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C et al. ( 2022 ) . Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses . Cancer Research vol. 82 , ( 4_Supplement )

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2022 ) . Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer . Cancer Research vol. 82 , ( 4_Supplement )

Schmid P, Baccan C, Guo Z, Tryfonidis K, Rugo HS ( 2022 ) . Abstract OT1-18-06: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer . Cancer Research vol. 82 , ( 4_Supplement )

Bardia A, Schmid P, Harbeck N, Rimawi MF, Hurvitz SA, Loi S, Saji S, Jung KH et al. ( 2022 ) . Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) . Cancer Research vol. 82 , ( 4_Supplement )

Kuemmel S, Gluz O, Reinisch M, Kostara A, Scheffen I, Graeser M, Luedtke-Heckenkamp K, Hartkopf A et al. ( 2022 ) . Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype . Cancer Research vol. 82 , ( 4_Supplement )

de Milliano T, Harding T, Seddik A, Schmid P, Oddsdottir J ( 2022 ) . Abstract P3-23-06: Assessment of select HER2-negative metastatic breast cancer (mBC) agents as a proxy to understand health technology assessment bodies uncertainties in HER2-low mBC agents in Germany, France, Spain, Italy and England . Cancer Research vol. 82 , ( 4_Supplement )

Schmid P, Nowecki Z, Im S-A, Chung W-P, Lord S, Armstrong A, Ma CX, Huisden R et al. ( 2022 ) . Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O) . Cancer Research vol. 82 , ( 4_Supplement )

Kuemmel S, Gluz O, Reinisch M, Kostara A, Scheffen I, Graeser M, Wuerstlein R, Nitz U et al. ( 2022 ) . Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype . Cancer Research vol. 82 , ( 4_Supplement )

Kaufman P, Martin M, Mayer I, Vahdat L, Pernas S, Schmid P, McArthur H, Dent R et al. ( 2022 ) . Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS) . Cancer Research vol. 82 , ( 4_Supplement )

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C et al. ( 2022 ) . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer . New England Journal of Medicine vol. 386 , ( 6 ) 556 - 567 .

Kümmel S, Cortés J, Dent R, Pusztai L, McArthur H, Bergh J, Denkert C, Park YH et al. ( 2022 ) . Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study . European Journal of Surgical Oncology vol. 48 , ( 2 ) e30 - e31 .

Huober J, Tolaney SM, De Azambuja E, Emens LA, Pan W, Huang J, Sun SW, Schmid P ( 2022 ) . ASCENT-04/KEYNOTE-D19: Phase 3 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in 1L programmed death-ligand 1-positive (PDL1+) metastatic triple-negative breast cancer (mTNBC) . SWISS MEDICAL WEEKLY . vol. 152 , 66S - 67S .

de Milliano T, Harding T, Seddik A, Oddsdottir J, Schmid P, Anastasaki E ( 2022 ) . ASSESSMENT OF SELECT HER2-NEGATIVE MBC AGENTS AS A PROXY TO UNDERSTAND HTAB UNCERTAINTIES IN HER2-LOW MBC AGENTS IN EU4 AND ENGLAND . VALUE IN HEALTH . vol. 25 , S175 - S175 .

Rogerson S, Turner H, Bilkhu A, Monturus E, Knott A, Restuccia E, Quashie N, Wheatley D et al. ( 2022 ) . Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Andre F, Hamilton EP, Loi S, Im S-A, Sohn J, Tseng L-M, Anders CK, Schmid P et al. ( 2022 ) . Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+(DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

De Laurentiis M, Costa L, Gligorov J, Knop A, Senkus-Konefka E, Garcia-Saenz JA, Schmid P, Heniquez A et al. ( 2022 ) . EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent RA, McArthur HL, Kuemmel S, Bergh JCS et al. ( 2022 ) . Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522 . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Molinero L, Guan X, Deurloo R, Gozlan Y, Sharim H, Emens LA, Cameron DA, Schmid P et al. ( 2022 ) . Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

McArthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, Park YH et al. ( 2022 ) . KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer . ANNALS OF SURGICAL ONCOLOGY . vol. 29 , 338 - 338 .

Rugo HS, Sohn J, Jerez Gilarranz Y, Gonzalez-Cortijo L, Sonnenblick A, Sabanathan D, Pablo Korbenfeld E, Egle D et al. ( 2022 ) . KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Bedard PL, Accordino MK, Cervantes A, Gambardella V, Hamilton EP, Italiano A, Juric D, Kalinsky K et al. ( 2022 ) . Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Molinero L, Emens LA, Goldstein LD, Abbas AR, Koeppen H, Rugo HS, Adams S, Chui SY et al. ( 2022 ) . Mechanisms of action and acquired resistance to atezolizumab plus <i>nab</i>-paclitaxel in metastatic triple-negative breast cancer (mTNBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C et al. ( 2022 ) . Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 18 , 117 - 118 .

de Milliano T, Harding T, Seddik A, Oddsdottir J, Schmid P, Anastasaki E ( 2022 ) . POSA284 Assessment of Select HER2-Negative MBC Agents as a Proxy to Understand HTAB Uncertainties in HER2-Low MBC Agents in EU4 and England . Value in Health vol. 25 , ( 1 )

Loi S, Cescon D, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2022 ) . Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy by PD-L1 Combined Positive Scores 1-9, 10-19, and >= 20 for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer: KEYNOTE-355 Subgroup Analysis . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 18 , 133 - 133 .

Schmid P, Sohn JH, Jerez Gilarranz Y, Gonzalez-Cortijo L, Sonnenblick A, Sabanathan D, Korbenfeld E, Egle D et al. ( 2022 ) . Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49 . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 18 , 233 - 234 .

Marme F, Rugo HS, Bardia A, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E et al. ( 2022 ) . Primary Results of TROPiCS-02: A Randomized Phase 3 Trial of Sacituzumab Govitecan vs. Physician's Treatment of Choice (TPC) in Patients with Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer . ONCOLOGY RESEARCH AND TREATMENT . vol. 45 , 105 - 105 .

Rugo HS, Bardia A, Marine F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E et al. ( 2022 ) . Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Cortes M, Salgado AC, Murillo SM, Blancas I, Cortez P, Plaza IC, Fernandez ND, Martinez-Bueno A et al. ( 2022 ) . Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 40 ,

Kolberg H-C, Andre F, Hamilton E, Loi S, Schmid P, Anders C, Yu T, Boston S et al. ( 2022 ) . Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) . ONCOLOGY RESEARCH AND TREATMENT . vol. 45 , 32 - 32 .

Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M et al. ( 2021 ) . Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer . JAMA Oncology vol. 7 , ( 12 ) 1791 - 1799 .

Schmid P ( 2021 ) . The use of immunotherapy in triple-negative breast cancer . Clinical Advances in Hematology and Oncology vol. 19 , ( 12 ) 770 - 773 .

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’ Annals of Oncology 2021; 32: 983-993 . Annals of Oncology vol. 32 , ( 12 )

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D et al. ( 2021 ) . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆ . Annals of Oncology vol. 32 , ( 12 ) 1475 - 1495 .

Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA et al. ( 2021 ) . Using DNA sequencing data to quantify T cell fraction and therapy response . Nature vol. 597 , ( 7877 ) 555 - 560 .

Schmid P, Bofill FJS, Bermejo B, Phillips M, Wheatley D, Neus F, Schem C, Stradella A et al. ( 2021 ) . 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer . Annals of Oncology vol. 32 , s411 - s412 .

Schmid P, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L et al. ( 2021 ) . 202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy . Annals of Oncology vol. 32 , s445 - s446 .

Schmid P, Gomez-Pardo P, Wheatley D, Roy P, Krabisch P, Thill M, Ledwidge S, Thompson A et al. ( 2021 ) . 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC . Annals of Oncology vol. 32 , s449 - s450 .

Cortés J, Cescon DW, Rugo HS, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH et al. ( 2021 ) . LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC . Annals of Oncology vol. 32 , s1289 - s1290 .

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C et al. ( 2021 ) . VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC . Annals of Oncology vol. 32 , ( 9 ) 1198 - 1200 .

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’ Annals of Oncology 2021; volume 32: 983–993 . Annals of Oncology vol. 32 , ( 10 )

Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z et al. ( 2021 ) . Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication . Annals of Oncology vol. 32 , ( 10 ) 1245 - 1255 .

Emancipator K, Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Nowecki Z et al. ( 2021 ) . Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119 . Pathology . vol. 53 , s47 - s48 .

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis . Annals of Oncology vol. 32 , ( 8 ) 983 - 993 .

Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P ( 2021 ) . Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply . The Lancet vol. 398 , ( 10294 ) 24 - 25 .

Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V et al. ( 2021 ) . PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer . Journal of the National Cancer Institute vol. 113 , ( 12 ) 1733 - 1743 .

Elizabeth C ( 2021 ) . Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand . AIDS vol. 35 , ( 12 ) 1973 - 1985 .

Schmid P, Bedard P, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K et al. ( 2021 ) . A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC) . Senologie - Zeitschrift für Mammadiagnostik und -therapie . Conference: Wissenschaftliche Abstracts zur 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. (DGS) Interdisziplinär. Kommunikativ. Digital vol. 18 , e36 - e37 .

Schmid P, Im S-A, Armstrong A, Park YH, Chung W-P, Nowecki Z, Lord S, Wysocki PJ et al. ( 2021 ) . BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 1023 - 1023 .

Schmid P, Nunes AT, Dry H, Dougherty R, Karwe V, Scheuring UJ ( 2021 ) . BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) tps1105 - tps1105 .

Moore HM, Boni V, Bellet M, De Las Heras BB, Cortés MG, Oakman C, Schmid P, Trinh XB et al. ( 2021 ) . Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 577 - 577 .

Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J et al. ( 2021 ) . Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study . npj Breast Cancer vol. 7 , ( 1 )

Jhaveri KL, Boni V, Sohn J, Villanueva-Vásquez R, Bardia A, Schmid P, Lim E, Patel JM et al. ( 2021 ) . Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 1017 - 1017 .

Emens LA, Goldstein LD, Schmid P, Rugo HS, Adams S, Barrios CH, Schneeweiss A, Dieras V et al. ( 2021 ) . The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130 . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 1006 - 1006 .

Andre F, Hamilton EP, Loi S, Schmid P, Anders CK, Yu T, Boston S, D'Cruz CM et al. ( 2021 ) . Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) tps1096 - tps1096 .

Pérez-García JM, Gebhart G, Borrego MR, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S et al. ( 2021 ) . Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial . The Lancet Oncology vol. 22 , ( 6 ) 858 - 871 .

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD et al. ( 2021 ) . Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer . New England Journal of Medicine vol. 384 , ( 16 ) 1529 - 1541 .

Hall PE, Schmid P ( 2021 ) . Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials . Expert Opinion on Emerging Drugs vol. 26 , ( 2 ) 131 - 147 .

Falchook G, Infante J, Arkenau H-T, Patel MR, Dean E, Borazanci E, Brenner A, Cook N et al. ( 2021 ) . First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors . EClinicalMedicine vol. 34 ,

Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L et al. ( 2021 ) . Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial . European Journal of Cancer vol. 148 , 382 - 394 .

Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R et al. ( 2021 ) . Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer . European Journal of Cancer vol. 148 , 134 - 145 .

Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K et al. ( 2021 ) . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 22 , ( 4 ) 499 - 511 .

Rugo HS, Schmid P, Cescon DW, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2021 ) . Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer . Cancer Research vol. 81 , ( 4_Supplement )

Andre F, Hamilton E, Loi S, Schmid P, Yu T, Lu S, Boston S, D'Cruz C et al. ( 2021 ) . Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) . Cancer Research vol. 81 , ( 4_Supplement )

Jhaveri K, Hamilton E, Loi S, Schmid P, Darilay A, Gao C, Patel G, Wrona M et al. ( 2021 ) . Abstract OT-03-05: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) . Cancer Research vol. 81 , ( 4_Supplement )

Rugo H, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, Schmid P, Cescon D et al. ( 2021 ) . Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . Cancer Research . vol. 81 ,

Schmid P, Abraham J, Chan S, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall P et al. ( 2021 ) . Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer . Cancer Research vol. 81 , ( 4_Supplement )

Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Laliman V et al. ( 2021 ) . Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC) . Cancer Research vol. 81 , ( 4_Supplement )

Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Nowecki Z, Schmid P et al. ( 2021 ) . Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119 . Cancer Research vol. 81 , ( 4_Supplement )

Emens L, Molinero L, Adams S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios C et al. ( 2021 ) . Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab and nab -paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial . Cancer Research vol. 81 , ( 4_Supplement )

Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer . Cancer Research . vol. 81 ,

Loi S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS, De Laurentiis M et al. ( 2021 ) . Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 . Cancer Research vol. 81 , ( 4_Supplement )

Pérez-García JM, Llombart-Cussac A, Bellet M, Dalenc F, Gil MJG, Borrego MR, Gavilá J, Sampayo-Cordero M et al. ( 2021 ) . Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL) . Cancer Research vol. 81 , ( 4_Supplement )

Winer E, Lipatov O, Im S-A, Goncalves A, Lee KS, Schmid P, Testa L, Witzel I et al. ( 2021 ) . Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases . Cancer Research vol. 81 , ( 4_Supplement )

Schmid P, Savas P, Espinosa E, Boni V, Italiano A, White S, Cheng K, Lam L et al. ( 2021 ) . Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) . Cancer Research vol. 81 , ( 4_Supplement )

Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH et al. ( 2021 ) . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study . Journal of the National Cancer Institute vol. 113 , ( 8 ) 1005 - 1016 .

Schmid P, Sablin M-P, Bergh J, Im S-A, Lu Y-S, Martínez N, Neven P, Lee KS et al. ( 2021 ) . A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer . Breast Cancer Research vol. 23 , ( 1 )

Bedard PL, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE et al. ( 2021 ) . A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,

Varghese J, Gohari S, Faheem M, Kümmel S, Johnson L, Schmid P ( 2021 ) . A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction . European Journal of Surgical Oncology vol. 47 , ( 1 )

Loi S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS, De laurentiis M et al. ( 2021 ) . Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 . CANCER RESEARCH . vol. 81 ,

Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER plus primary breast cancer . CANCER RESEARCH . vol. 81 ,

Emens L, Molinero L, Adams S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, Barrios C et al. ( 2021 ) . Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial . CANCER RESEARCH . vol. 81 ,

Varghese JS, Gohari S, Shawky M, Hyun F, Johnson L, Schmid P ( 2021 ) . Impact of neoadjuvant chemotherapy on breast reconstruction - systematic review and meta-analysis . CANCER RESEARCH . vol. 81 ,

Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Laliman V et al. ( 2021 ) . Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC) . CANCER RESEARCH . vol. 81 ,

Manuel Perez-Garcia J, Llombart-Cussac A, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavila J, Sampayo-Cordero M et al. ( 2021 ) . Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL) . CANCER RESEARCH . vol. 81 ,

Winer E, Lipatov O, Im S-A, Goncalves A, Lee KS, Schmid P, Testa L, Witzel I et al. ( 2021 ) . Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases . CANCER RESEARCH . vol. 81 ,

Turner N, Jhaveri K, Kalinsky K, Loibl S, Loi S, Im S-A, Saura C, Schmid P et al. ( 2021 ) . Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with <i>PIK3CA</i>-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC) . CANCER RESEARCH . vol. 81 ,

Jhaveri K, Juric D, Varga A, Turner N, Schmid P, Saura C, Oliveira M, Krop IE et al. ( 2021 ) . Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,

Olivera M, Jhaveri K, Juric D, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A et al. ( 2021 ) . Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,

Andre F, Hamilton E, Loi S, Schmid P, Yu T, Lu S, Boston S, D'Cruz C et al. ( 2021 ) . Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) . CANCER RESEARCH . vol. 81 ,

Jhaveri K, Hamilton E, Loi S, Schmid P, Darilay A, Gao C, Patel G, Wrona M et al. ( 2021 ) . Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) . CANCER RESEARCH . vol. 81 ,

Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortés J, Ramsey SD, Briggs A, Hu P et al. ( 2020 ) . Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis . Cancer Research vol. 80 , ( 24 ) 5427 - 5434 .

Varghese J, Gohari SS, Rizki H, Faheem I, Langridge B, Kümmel S, Johnson L, Schmid P ( 2020 ) . A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction . The Breast vol. 55 , 55 - 62 .

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2020 ) . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial . The Lancet vol. 396 , ( 10265 ) 1817 - 1828 .

Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, Ní Dhochartaigh S, Tran I, Leslie I et al. ( 2020 ) . Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage . Health and Quality of Life Outcomes vol. 18 , ( 1 )

Dent R, Cortes J, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C, Park YH et al. ( 2020 ) . 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) . Annals of Oncology vol. 31 , s1241 - s1242 .

Yusof MM, Cescon DW, Rugo HS, Im S-A, Gallardo C, Lipatov O, Barrios CH, Holgado E et al. ( 2020 ) . 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia . Annals of Oncology vol. 31 ,

Im S-A, Cortes J, Lipatov O, Goncalves A, Lee K-S, Schmid P, Tamura K, Testa L et al. ( 2020 ) . 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation . Annals of Oncology . vol. 31 ,

Iwata H, Emens L, Adams S, Barrios CH, Diéras V, Loi S, Rugo HS, Schneeweiss A et al. ( 2020 ) . 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer . Annals of Oncology vol. 31 , s1261 - s1262 .

Saji S, Cussac AL, Andre F, Robson ME, Harbeck N, Schmid P, Cescon DW, Ahn JS et al. ( 2020 ) . 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC . Annals of Oncology vol. 31 ,

Emens LA, Adams S, Barrios CH, Dieras VC, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2020 ) . IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer . Annals of Oncology vol. 31 ,

Rugo HS, Cussac AL, André F, Robson M, Saji S, Harbeck N, Schmid P, Cescon DW et al. ( 2020 ) . A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 . Annals of Oncology vol. 31 ,

Martínez SG, Mies BP, Casas TC, Rosa JMR, Peralto JLR, Curigliano G, Schmid P, Kümmel S et al. ( 2020 ) . Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis . Annals of Oncology . vol. 31 ,

Bruzas S, Kümmel S, Harbeck N, Schmid P, Cortés J, Seiberling C, Chiari O, Harrach H et al. ( 2020 ) . Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis . Annals of Oncology vol. 31 ,

Kaufman PA, Martin M, Mayer I, Vahdat LT, Simon SP, Schmid P, McArthur HL, Dent R et al. ( 2020 ) . International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS) . Annals of Oncology vol. 31 , s394 - s395 .

Gambardella V, Cervantes A, Bedard PL, Hamilton EP, Italiano A, Jhaveri K, Juric D, Kalinsky K et al. ( 2020 ) . PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) . Annals of Oncology . vol. 31 , s381 - s382 .

Turner N, Jhaveri K, Kalinsky K, Loibl S, Loi S, Im S-A, Saura C, Schmid P et al. ( 2020 ) . Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) . Annals of Oncology . vol. 31 , s391 - s392 .

Emens LA, Molinero L, Adams S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH et al. ( 2020 ) . Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial . Annals of Oncology vol. 31 , s360 - s361 .

Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P et al. ( 2020 ) . A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer . Clinical Cancer Research vol. 26 , ( 16 ) 4242 - 4249 .

Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, Karantza V et al. ( 2020 ) . Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer . Journal of the National Comprehensive Cancer Network vol. 18 , ( 8 ) 1096 - 1104 .

Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ ( 2020 ) . The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer . Breast Cancer Research and Treatment vol. 183 , ( 3 ) 629 - 638 .

Schmid P, Kümmel S, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S et al. ( 2020 ) . Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC) . Geburtshilfe und Frauenheilkunde vol. 80 , ( 06 ) e44 - e45 .

Cetin B, Gumusay O ( 2020 ) . Pembrolizumab for Early Triple-Negative Breast Cancer . New England Journal of Medicine vol. 382 , ( 26 )

Schmid P, Kümmel S, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S et al. ( 2020 ) . Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC) . Senologie - Zeitschrift für Mammadiagnostik und -therapie . Conference: 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. vol. 17 , e26 - e27 .

Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M et al. ( 2020 ) . Publisher Correction: A clonal expression biomarker associates with lung cancer mortality . Nature Medicine vol. 26 , ( 7 ) 1148 - 1148 .

Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA et al. ( 2020 ) . Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse . Nature Medicine vol. 26 , ( 7 ) 1147 - 1147 .

Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T et al. ( 2020 ) . Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer . Nature Medicine vol. 26 , ( 7 ) 1148 - 1148 .

AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA et al. ( 2020 ) . Geospatial immune variability illuminates differential evolution of lung adenocarcinoma . Nature Medicine vol. 26 , ( 7 ) 1054 - 1062 .

Schmid P, Cortes J, Robson ME, Iwata H, Hegg R, Nechaeva M, Xu B, Verma S et al. ( 2020 ) . A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps1109 - tps1109 .

Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Testa L et al. ( 2020 ) . Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119 . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1013 - 1013 .

Cortes J, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Escrivá S, Calvo Martínez L, Ribelles N et al. ( 2020 ) . Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 503 - 503 .

Rugo HS, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, Schmid P, Cescon DW et al. ( 2020 ) . KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps596 - tps596 .

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2020 ) . KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1000 - 1000 .

Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M et al. ( 2020 ) . PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1007 - 1007 .

Conte PF, Dieci MV, Bisagni G, De Laurentiis M, Tondini CA, Schmid P, De Salvo GL, Moratello G et al. ( 2020 ) . Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps598 - tps598 .

Schmid-Araya JM, Schmid PE, Majdi N, Traunspurger W ( 2020 ) . Biomass and production of freshwater meiofauna: a review and a new allometric model . Hydrobiologia vol. 847 , ( 12 ) 2681 - 2703 .

Schmid P, Haiderali A, Mejia J, Guo Z, Zhou X, Martin-Nguyen A, Cortés J, Winer E ( 2020 ) . 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer . Annals of Oncology . vol. 31 , s65 - s66 .

Schmid P, Rugo HS, Cortés J, Blum P, Crossley K, Massey D, Burris HA ( 2020 ) . 181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1) . Annals of Oncology . vol. 31 ,

Schmid PE, Schmid-Araya JM, Tokeshi M ( 2020 ) . The scaling of biomass variance across trophic levels in stream species communities: a macroecological approach . Hydrobiologia vol. 847 , ( 12 ) 2705 - 2723 .

Schmid P, Cortes L, Pusztai L ( 2020 ) . Pembrolizumab plus Neoadjuvant Chemotherapy Improves Pathologic Complete Response Rates in Triple-Negative Breast Cancer . Journal of Clinical Outcomes Management vol. 27 , ( 2 ) 53 - 55 .

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al. ( 2020 ) . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer . Future Oncology vol. 16 , ( 12 ) 705 - 715 .

López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK et al. ( 2020 ) . Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution . Nature Genetics vol. 52 , ( 3 ) 283 - 293 .

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al. ( 2020 ) . Pembrolizumab for Early Triple-Negative Breast Cancer . New England Journal of Medicine vol. 382 , ( 9 ) 810 - 821 .

Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al. ( 2020 ) . Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer . Annals of Oncology vol. 31 , ( 5 ) 582 - 589 .

Cortes J, Perez‐García JM, Llombart‐Cussac A, Curigliano G, Saghir NSE, Cardoso F, Barrios CH, Wagle S et al. ( 2020 ) . Enhancing global access to cancer medicines . CA A Cancer Journal for Clinicians vol. 70 , ( 2 ) 105 - 124 .

Schmid P ( 2020 ) . Abstract ES1-2: Detecting and Managing Immunotherapy-related Toxicities Wisely . Cancer Research vol. 80 , ( 4_Supplement )

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al. ( 2020 ) . Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) . Cancer Research . vol. 80 ,

Juric D, Kalinsky K, Oliveira M, Cervantes A, Bedard P, Krop I, Hamilton E, Schmid P et al. ( 2020 ) . Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA -mutant solid tumors . Cancer Research . vol. 80 ,

Kaufmann P, Cortes J, Martin M, Mayer I, Vahdat L, Pernas S, Schmid P, McArthur H et al. ( 2020 ) . Abstract OT1-08-06: International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) . Cancer Research . vol. 80 ,

Schmid P, Cortes J, Robson M, Iwata H, Hegg R, Verma S, Nechaeva M, Xu B et al. ( 2020 ) . Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290) . Cancer Research . vol. 80 ,

Jhaveri K, Kalinsky K, Bedard P, Cervantes A, Saura C, Krop I, Hamilton E, Schmid P et al. ( 2020 ) . Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA -mutant HR+/HER2- breast cancer . Cancer Research . vol. 80 ,

Pérez-García JM, Llombart-Cussac A, Holgado E, Curigliano G, Miranda EL, Alonso-Romero JL, Bermejo B, Calvo L et al. ( 2020 ) . Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) . Cancer Research . vol. 80 ,

Cameron D, Symeonides S, Brunt M, Schmid P, Waters S, Twelves C, Barrett-Lee P, Bartlett J et al. ( 2020 ) . Abstract P3-11-09: ARISTACAT - Ar omatase i nhibition plus minus s araca t inib as a dvanced breast ca ncer t herapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer . Cancer Research . vol. 80 ,

Casadevall D, Mestres JA, Rojo F, Bellosillo B, González A, Serra V, Bellet M, Gil MA et al. ( 2020 ) . Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial . Cancer Research . vol. 80 ,

Robertson JF, Evans A, Henschen S, Kirwan C, Jahan A, Kenny L, Dixon JM, Schmid P et al. ( 2020 ) . Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer . Cancer Research . vol. 80 ,

Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V et al. ( 2020 ) . Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 . Cancer Research . vol. 80 ,

Loi S, Winer E, Lipatov O, Im S-A, Goncalves A, Cortes J, Lee KS, Schmid P et al. ( 2020 ) . Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) . Cancer Research . vol. 80 ,

Reinisch M, Gluz O, Ataseven B, Schmid P, Blohmer J-U, Dittmer-Grabwoski C, Rueland A, Bruzas S et al. ( 2020 ) . Abstract PD5-09: Prognostic and predictive impact of genes and signatures measured with the BC360 panel (Nanostring) in node positive (≥pN2a) high risk patients (pts) receiving dose dense (dd) versus standard dosed chemotherapy in an adjuvant randomized trial with a long term follow-up (FU) . Cancer Research . vol. 80 ,

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im S-A, Foukakis T et al. ( 2020 ) . Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study . Annals of Oncology vol. 31 , ( 5 ) 569 - 581 .

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al. ( 2020 ) . Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial . Journal of Clinical Oncology vol. 38 , ( 5 ) 423 - 433 .

Schmid P, Cortes J, Robson ME, Iwata H, Hegg R, Nechaeva M, Xu B, Verma S et al. ( 2020 ) . A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Winer EP, Lipatov O, Im S-A, Goncalves A, Munoz-Couselo E, Lee KS, Schmid P, Testa L et al. ( 2020 ) . Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119 . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Cortes J, Gebhart G, Borrego MR, Stradella A, Bermejo B, Escriva S, Martinez LC, Ribelles N et al. ( 2020 ) . Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Rugo HS, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, Schmid P, Cescon DW et al. ( 2020 ) . KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Schmid P ( 2020 ) . KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups . ANNALS OF SURGICAL ONCOLOGY . vol. 27 , S129 - S129 .

Hirshfield K, Cardoso F, Bardia A, Andre F, Cescon D, McArthur H, Telli M, Loi S et al. ( 2020 ) . KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer . ANNALS OF SURGICAL ONCOLOGY . vol. 27 , S288 - S288 .

Llombart-Cussac A, Perez-Garcia JM, Bellet M, Dalenc F, Gil MJG, Borrego MR, Gavila J, Sampayo-Cordero M et al. ( 2020 ) . PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Burrell RA, Kumar SS, Kateb A, Dougall G, Wulff J, Benson J, Forouhi P, Agrawal A et al. ( 2020 ) . PIONEER: pre-operative window study of letrozole plus progesterone receptor agonist megestrol acetate versus letrozole alone in post-menopausal patients with oestrogen receptor-positive breast cancer . BREAST CANCER RESEARCH AND TREATMENT . vol. 180 , 542 - 542 .

Rugo HS, Loi S, Adams S, von Moos R, Schmid P, Schneeweiss A, Barrios CH, Iwata H et al. ( 2020 ) . Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130 . SWISS MEDICAL WEEKLY . 31S - 31S .

Conte PF, Dieci MV, Bisagni G, De Laurentiis M, Tondini CA, Schmid P, De Salvo GL, Moratello G et al. ( 2020 ) . Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V et al. ( 2019 ) . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 44 - 59 .

Thompson A, Wölmer N, Koncarevic S, Selzer S, Böhm G, Legner H, Schmid P, Kienle S et al. ( 2019 ) . TMTpro: Design, Synthesis, and Initial Evaluation of a Proline-Based Isobaric 16-Plex Tandem Mass Tag Reagent Set . Analytical Chemistry vol. 91 , ( 24 ) 15941 - 15950 .

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2019 ) . Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer . JAMA Oncology vol. 5 , ( 11 ) 1556 - 1563 .

Cardoso F, Bardia A, André F, Cescon DW, McArthur H, Telli M, Loi S, Cortes J et al. ( 2019 ) . 24TiP KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer . Annals of Oncology vol. 30 , ix7 - ix8 .

Iwata H, Im S-A, Sohn J, Jung KH, Im Y-H, Lee KS, Inoue K, Tamura K et al. ( 2019 ) . 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries . Annals of Oncology vol. 30 , ix13 - ix14 .

Cussac AL, Medioni J, Colleoni MA, Ettl J, Schmid P, Macpherson I, Gligorov J, Albanell J et al. ( 2019 ) . 387TiP Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial . Annals of Oncology vol. 30 ,

Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras VC et al. ( 2019 ) . LBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 . Annals of Oncology vol. 30 , v858 - v859 .

Cortés J, Lipatov O, Im S-A, Gonçalves A, Lee KS, Schmid P, Tamura K, Testa L et al. ( 2019 ) . LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) . Annals of Oncology vol. 30 , v859 - v860 .

Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C et al. ( 2019 ) . LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) . Annals of Oncology vol. 30 , v853 - v854 .

Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Singel SM et al. ( 2019 ) . Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) . Cancer Research . vol. 79 , ct049 - ct049 .

Loi S, Schmid P, Cortés J, Cescon DW, Winer EP, Toppmeyer D, Rugo HS, Laurentiis MD et al. ( 2019 ) . Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 . Cancer Research . vol. 79 ,

Schneeweiss A, Rugo HS, Winer EP, Barrios CH, Iwata H, Dieras V, Loi S, Maiya V et al. ( 2019 ) . IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1068 - 1068 .

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V et al. ( 2019 ) . IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1003 - 1003 .

Cardoso F, Bardia A, Andre F, Cescon DW, McArthur HL, Telli ML, Loi S, Cortes J et al. ( 2019 ) . KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer . Journal of Clinical Oncology . vol. 37 , tps601 - tps601 .

Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al. ( 2019 ) . Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1067 - 1067 .

Schmid P, Rugo HS, Cortes J, Huang C-L, Crossley K, Massey D, Burris HA ( 2019 ) . XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement . Journal of Clinical Oncology . vol. 37 , tps1103 - tps1103 .

Winters Z, Roberts N, McCartan N, Potyka I, Brunt M, Maxwell A, Greenwood R, Ingram J et al. ( 2019 ) . 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) . European Journal of Surgical Oncology vol. 45 , ( 5 )

Loi S, Schmid P, Aktan G, Karantza V, Salgado R ( 2019 ) . 4O Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial . Annals of Oncology vol. 30 ,

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM et al. ( 2019 ) . IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer . Future Oncology vol. 15 , ( 17 ) 1951 - 1961 .

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M et al. ( 2019 ) . Neoantigen-directed immune escape in lung cancer evolution . Nature vol. 567 , ( 7749 ) 479 - 485 .

Aktas BY, Taban H, Aksoy S ( 2019 ) . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer . New England Journal of Medicine vol. 380 , ( 10 ) 985 - 988 .

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al. ( 2019 ) . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 397 - 404 .

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2019 ) . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 405 - 411 .

Emens L, Loi S, Rugo H, Schneeweiss A, Diéras V, Iwata H, Barrios C, Nechaeva M et al. ( 2019 ) . Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer . Cancer Research . vol. 79 ,

Yardley D, Abu-Khalaf M, Boni V, Brufsky A, Emens L, Gutierrez M, Hurvitz S, Im S-A et al. ( 2019 ) . Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer . Cancer Research . vol. 79 ,

Schmid P, Nunes A, Lall R, D'Cruz C, Grinsted L, Lanasa M ( 2019 ) . Abstract OT3-01-01: BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC) . Cancer Research . vol. 79 ,

Cardoso F, Bardia A, Andre F, Cescon D, McArthur H, Telli M, Loi S, Cortés J et al. ( 2019 ) . Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer . Cancer Research . vol. 79 ,

Schmid P, Pinder S, Wheatley D, Zummit C, Macaskill E, Hu J, Price R, Bundred N et al. ( 2019 ) . Abstract P2-08-02: Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer . Cancer Research . vol. 79 ,

Loi S, Schmid P, Cortés J, Park Y, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A et al. ( 2019 ) . Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial . Cancer Research . vol. 79 ,

Vahdat L, Forero-Torres A, Schmid P, Blackwell K, Telli M, Melisko M, Holgado E, Moebus V et al. ( 2019 ) . Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC) . Cancer Research . vol. 79 ,

Crown J, Sablin M-P, Cortés J, Bergh J, Im S-A, Lu Y-S, Martínez N, Neven P et al. ( 2019 ) . Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results . Cancer Research . vol. 79 ,

Schmid P, Park Y, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A, Holgado E, Foukakis T et al. ( 2019 ) . Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC) . Cancer Research . vol. 79 ,

Winters Z, Roberts N, Brunt M, Greenwood R, Maxwell A, Potyka I, Ingram J, Kandiyali R et al. ( 2019 ) . Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK . ANNALS OF SURGICAL ONCOLOGY . vol. 26 , 58 - 60 .

von Moos R, Emens LA, Loi S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, Barrios CH et al. ( 2019 ) . IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC . SWISS MEDICAL WEEKLY . vol. 149 , 13S - 14S .

Cortes J, Lipatov O, Im S-A, Goncalves A, Lee KS, Schmid P, Tamura K, Testa L et al. ( 2019 ) . KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) . ANNALS OF ONCOLOGY . vol. 30 , 859 - + .

Schmid P, Cortes J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C et al. ( 2019 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) . ANNALS OF ONCOLOGY . vol. 30 , 853 - 854 .

Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H, Telli M, Loi S, Cortes J et al. ( 2019 ) . KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer . ANNALS OF ONCOLOGY . vol. 30 ,

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R et al. ( 2019 ) . Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study . JAMA Oncology vol. 5 , ( 1 ) 74 - 82 .

Llombart Cussac A, Medioni J, Colleoni MA, Ettl J, Schmid P, Macpherson I, Gligorov J, Albanell J et al. ( 2019 ) . Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial . ANNALS OF ONCOLOGY . vol. 30 ,

Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras VC et al. ( 2019 ) . Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 . ANNALS OF ONCOLOGY . vol. 30 , 858 - + .

Loi S, Schmid P, Aktan G, Karantza V, Salgado R ( 2019 ) . Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial . ANNALS OF ONCOLOGY . vol. 30 ,

Iwata H, Im S-A, Sohn J, Jung KH, Im Y-H, Lee KS, Inoue K, Tamura K et al. ( 2019 ) . Subgroup analysis of IMpassion130: Atezolizumab plus nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries . ANNALS OF ONCOLOGY . vol. 30 ,

Schmid P, Rugo HS, Cortes J, Huang DC-L, Crossley K, Massey D, Burris HAIII ( 2019 ) . XENERA™-1: A phase II trial of xentuzumab (Xe) in combinationwith everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 158 - 158 .

Crown J, Sablin M-P, Cortes J, Bergh J, Im S-A, Lu Y-S, Martinez N, Neven P et al. ( 2019 ) . Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomised phase 2 results . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 173 - 173 .

Crown J, Sablin M-P, Cortes J, Bergh J, Im S-A, Lu Y-S, Martinez N, Neven P et al. ( 2019 ) . Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomized Phase 2 Results . BRITISH JOURNAL OF CANCER . vol. 121 , 20 - 20 .

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ et al. ( 2018 ) . FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC . Journal of Thoracic Oncology vol. 13 , ( 11 ) 1733 - 1742 .

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R et al. ( 2018 ) . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer . New England Journal of Medicine vol. 379 , ( 22 ) 2108 - 2121 .

Schmid P ( 2018 ) . ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer . ESMO Open vol. 3 , ( 6 )

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I et al. ( 2018 ) . Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) . Proceedings of the National Academy of Sciences of the United States of America vol. 115 , ( 43 ) e10119 - e10126 .

Chau I, Haag GM, Rahma OE, Macarulla TM, McCune SL, Yardley DA, Solomon BJ, Johnson M et al. ( 2018 ) . 1239TiP MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types . Annals of Oncology . vol. 29 , viii439 - viii440 .

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al. ( 2018 ) . LBA1_PR IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) . Annals of Oncology vol. 29 , viii707 - viii708 .

Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R et al. ( 2018 ) . MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC . Journal of Thoracic Oncology . vol. 13 ,

García JMP, Llombart A, Alonso JL, Bermejo B, Calvo L, Carañana V, Curigliano G, Sánchez SDLC et al. ( 2018 ) . Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) . Cancer Research . vol. 78 , ct152 - ct152 .

Winters Z, Horsnell J, Elvers K, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al. ( 2018 ) . A systematic review of the impact of breast conserving surgery on cancer outcomes of multiple ipsilateral breast cancers (MIBC)–the case for a randomised trial . European Journal of Surgical Oncology vol. 44 , ( 6 )

Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al. ( 2018 ) . Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers . BJS Open vol. 2 , ( 4 ) 162 - 174 .

Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH et al. ( 2018 ) . AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial . Journal of Clinical Oncology . vol. 36 , 1007 - 1007 .

Dent R, Andre F, Goncalves A, Kummel S, Martin M, Schmid P, Schuetz F, Swain SM et al. ( 2018 ) . IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps1115 - tps1115 .

Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. ( 2018 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . Journal of Clinical Oncology . vol. 36 , tps602 - tps602 .

Kim D-W, Gadgeel SM, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A et al. ( 2018 ) . Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK + advanced NSCLC (aNSCLC) . Journal of Clinical Oncology . vol. 36 , 9009 - 9009 .

Winter H, Rumbles S, Hughes B, O'Brien M, Rahman S, Murias C, Conibear J, Harries M et al. ( 2018 ) . Virtual metastatic breast multidisciplinary meeting: The next step in personalised medicine . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) e18794 - e18794 .

Schmid PJ, García-Gutierrez A, Jiménez J ( 2018 ) . Description and detection of burst events in turbulent flows . Journal of Physics Conference Series . vol. 1001 ,

Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH et al. ( 2018 ) . Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies . Cancer Cell vol. 33 , ( 4 ) 649 - 663.e4 .

Garassino MC, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, Jaime JC, Gray JE et al. ( 2018 ) . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study . The Lancet Oncology vol. 19 , ( 4 ) 521 - 536 .

Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker A-M, Kapitonova E, Bakhouche BA, Tanner Y et al. ( 2018 ) . PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer . Cell Reports vol. 22 , ( 9 ) 2469 - 2481 .

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2018 ) . Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer . Cancer Research . vol. 78 ,

Llombart-Cussac A, Curigliano G, Gebhart G, Gligorov J, Khaldoun K, Marmé F, Prat A, Schmid P et al. ( 2018 ) . Abstract OT1-03-01: Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study . Cancer Research vol. 78 , ( 4_Supplement )

Molinero L, Chang C-W, Udyavar A, Fasso M, O'Hear C, Emens L, Cruz C, Hegde P et al. ( 2018 ) . Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) . Cancer Research vol. 78 , ( 4_Supplement )

Verrill M, Wardley A, Retzler J, Smith A, McNicol D, Dando S, Tran I, Leslie I et al. ( 2018 ) . Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer . Cancer Research vol. 78 , ( 4_Supplement )

Schmid P, Dent R, Sohn J, Park Y, Muñoz-Couselo E, Kim S-B, Im S-A, Holgado E et al. ( 2018 ) . Abstract PD6-12: Withdrawn . Cancer Research vol. 78 , ( 4_Supplement )

Santos, Cozzi‐Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al. ( 2018 ) . Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe . HIV Medicine vol. 19 , ( 5 ) 324 - 338 .

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P et al. ( 2018 ) . Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer . Journal of Clinical Oncology vol. 36 , ( 9 )

Llombart-Cussac A, Curigliano G, Gebhart G, Gligorov J, Khaldoun K, Marme F, Prat A, Schmid P et al. ( 2018 ) . Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study . CANCER RESEARCH . vol. 78 ,

Adams S, Loi S, Toppmeyer DL, Cescon DW, De laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2018 ) . KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) . CANCER RESEARCH . vol. 78 ,

Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. ( 2018 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,

Molinero L, Chang C-W, Udyavar A, Fasso M, O'Hear C, Emens L, Cruz C, Hegde P et al. ( 2018 ) . Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) . CANCER RESEARCH . vol. 78 ,

Buchecker T, Schmid P, Renaudineau S, Diat O, Proust A, Pfitzner A, Bauduin P ( 2018 ) . Polyoxometalates in the Hofmeister series . Chemical Communications vol. 54 , ( 15 ) 1833 - 1836 .

Verrill M, Wardley A, Retzler J, Smith AB, McNicol D, Dando S, Tran I, Leslie I et al. ( 2018 ) . Quality of life and ability to work in patients at different disease stages of HER2+breast cancer . CANCER RESEARCH . vol. 78 ,

Roen A, Laut K, Pelchen‐Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, Monforte AD et al. ( 2017 ) . Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort . HIV Medicine vol. 19 , ( 4 ) 252 - 260 .

Group EBCTC, Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F et al. ( 2017 ) . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials . The Lancet Oncology vol. 19 , ( 1 ) 27 - 39 .

O'Leary K, Shia A, Schmid P ( 2017 ) . Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer . Curr Cancer Drug Targets vol. 18 , ( 1 ) 89 - 96 .

Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P ( 2017 ) . Nivolumab in HIV-related non-small-cell lung cancer . Annals of Oncology vol. 28 , ( 11 )

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S et al. ( 2017 ) . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution . Cell vol. 171 , ( 6 ) 1259 - 1271.e11 .

Cortés J, Im S-A, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M ( 2017 ) . The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies . Cancer Treatment Reviews vol. 61 , 53 - 60 .

Cozzi‐Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al. ( 2017 ) . Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens . HIV Medicine vol. 19 , ( 2 ) 102 - 117 .

Ruf M-T, Steffen C, Bolz M, Schmid P, Pluschke G ( 2017 ) . Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria . Virulence vol. 8 , ( 8 ) 1918 - 1926 .

De Laurentiis M, Montemurro F, Bachelot T, Martin M, Barrios C, Kaufman B, Schmid P, Alba E et al. ( 2017 ) . C45 The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials program . Annals of Oncology vol. 28 ,

Verrill M, Schmid P, Retzler J, Smith, Bottomley C, Dando S, Tran I, Leslie I et al. ( 2017 ) . PCN234 Work Productivity in HER2 Positive Breast Cancer: A Comparison of Patients Across Stages of Early and Metastatic Disease . Value in Health vol. 20 , ( 9 )

Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A ( 2017 ) . PCN86 Societal Costs of Er+/Her2- Advanced or Metastatic Breast Cancer in Post-Menopausal Women in The United Kingdom . Value in Health vol. 20 , ( 9 )

Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F et al. ( 2017 ) . Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial . The Lancet Gastroenterology & Hepatology vol. 2 , ( 12 ) 877 - 889 .

Schmid P, Castan JC, Bergh J, Pusztai L, Denkert C, Verma S, McArthur HL, Zhao J et al. ( 2017 ) . 233TiP KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . Annals of Oncology vol. 28 ,

Jimenez MM, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. ( 2017 ) . 323TiP EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) . Annals of Oncology vol. 28 ,

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . ANNALS OF ONCOLOGY . Conference: ESMO vol. 28 ,

Loi S, Adams S, Schmid P, Cortés J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2017 ) . LBA13 Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 . Annals of Oncology vol. 28 ,

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . Annals of Oncology vol. 28 ,

Shepherd L, Borges Á, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al. ( 2017 ) . The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people . HIV Medicine vol. 19 , ( 2 ) 90 - 101 .

Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP et al. ( 2017 ) . Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease . New England Journal of Medicine vol. 377 , ( 13 ) 1217 - 1227 .

Chupin J, Nagano A, Haley V, Lenihan C, Cavicchioli F, O’Leary K, Sahgal N, Nigro CL et al. ( 2017 ) . Abstract 104: miRNAs in the 14q32 cluster are involved in lapatinib resistance . Cancer Research . vol. 77 , 104 - 104 .

Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, Nanda R, Chung C et al. ( 2017 ) . Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses . Cancer Research vol. 77 , ( 13_Supplement ) 2986 - 2986 .

Nathan MR, Schmid P ( 2017 ) . The emerging world of breast cancer immunotherapy . The Breast vol. 37 , 200 - 206 .

Schmid P, Forster MD, Summers YJ, Good J, Sarker S-J, Lim L, Mousa K, Middleton GW ( 2017 ) . A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results . JOURNAL OF CLINICAL ONCOLOGY . Conference: ESMO vol. 35 ,

Hiley CT, Ahmad T, Jamal-Hanjani M, Abbosh C, Ngai Y, Hackshaw A, Patterson P, Baijal S et al. ( 2017 ) . Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II) . Journal of Clinical Oncology . vol. 35 , tps9099 - tps9099 .

Traina TA, Yardley DA, Schwartzberg LS, O'Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME et al. ( 2017 ) . Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 1089 - 1089 .

Schmid P, Park YH, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A, Holgado E, Wang Y et al. ( 2017 ) . Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173 . Journal of Clinical Oncology . vol. 35 , 556 - 556 .

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al. ( 2017 ) . Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A . Journal of Clinical Oncology . vol. 35 , 1008 - 1008 .

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2017 ) . Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 1088 - 1088 .

Nathan MR, Schmid P ( 2017 ) . A Review of Fulvestrant in Breast Cancer . Oncology and Therapy vol. 5 , ( 1 ) 17 - 29 .

Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA ( 2017 ) . Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial . TRIALS . Conference: ICTMC/SCT 2017 vol. 18 ,

Ruf M, Andreoli A, Vujic G, Itin P, Pluschke G, Schmid P ( 2017 ) . Exudate collection using wound sponges—An easy, non‐invasive and reliable method to explore protease activities in ulcers . Wound Repair and Regeneration vol. 25 , ( 2 ) 320 - 326 .

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA et al. ( 2017 ) . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution . Nature vol. 545 , ( 7655 ) 446 - 451 .

Vargas FA, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Rota EM, Dahan R et al. ( 2017 ) . Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors . Immunity vol. 46 , ( 4 ) 577 - 586 .

Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P et al. ( 2017 ) . Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers . Journal of Clinical Oncology vol. 35 , ( 16 )

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S et al. ( 2017 ) . Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR) . Journal of Clinical Oncology vol. 35 , ( 14 )

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink H-J, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al. ( 2017 ) . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort . Clinical Infectious Diseases vol. 64 , ( 10 ) 1413 - 1421 .

López-Miranda E, Gávila J, Pernas S, Saura C, Oliveira M, Serra V, Schmid P, Lord S et al. ( 2017 ) . Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007) . Cancer Research . vol. 77 ,

Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P ( 2017 ) . Abstract P3-03-12: CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy . Cancer Research . vol. 77 ,

Brenner A, Falchook G, Patel M, Infante J, Arkenau H-T, Dean E, Borazanci E, Lopez J et al. ( 2017 ) . Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel . Cancer Research vol. 77 , ( 4_Supplement )

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial . JAMA Oncology vol. 3 , ( 1 ) 58 - 66 .

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial . JAMA Oncology vol. 3 , ( 1 ) E1 - E9 .

Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. ( 2017 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 134 - 134 .

Martin Jimenez M, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. ( 2017 ) . EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC) . ANNALS OF ONCOLOGY . vol. 28 ,

Possinger K, Regierer A, Eucker J, Dieing A, Eucker J, Flath B, Folprecht G, Geißler M et al. ( 2017 ) . Herausgeber- und Autorenverzeichnis . Facharztwissen Hämatologie Onkologie , Elsevier

Mok T, Schmid P, De Castro G, Syrigos K, Martin C, Yamamoto N, Arén O, Arrieta O et al. ( 2017 ) . P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study Topic: Phase III . Journal of Thoracic Oncology . vol. 12 ,

Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R et al. ( 2017 ) . P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT . Journal of Thoracic Oncology . vol. 12 , s1302 - s1303 .

Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2017 ) . Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 . ANNALS OF ONCOLOGY . vol. 28 ,

Bermingham S, Schmid P, Forster F, Comic L, Theti D, Smith A ( 2017 ) . SOCIETAL COSTS OF ER+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN IN THE UNITED KINGDOM . VALUE IN HEALTH . vol. 20 , A427 - A427 .

Verrill M, Schmid P, Retzler J, Smith AB, Bottomley CJ, Dando S, Tran I, Leslie I et al. ( 2017 ) . WORK PRODUCTIVITY IN HER2 POSITIVE BREAST CANCER: A COMPARISON OF PATIENTS ACROSS STAGES OF EARLY AND METASTATIC DISEASE . VALUE IN HEALTH . vol. 20 , A454 - A454 .

Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. ( 2016 ) . 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC . Annals of Oncology vol. 27 ,

Mok T, Schmid P, de Castro G, Syrigos K, Martin C, Yamamoto N, Arén O, Arrieta O et al. ( 2016 ) . 482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE . Annals of Oncology vol. 27 ,

Schmid‐Araya JM, Schmid PE, Tod SP, Esteban GF ( 2016 ) . Trophic positioning of meiofauna revealed by stable isotopes and food web analyses . Ecology vol. 97 , ( 11 ) 3099 - 3109 .

Schmid P, Pinder SE, Purushotham A, Thompson AM ( 2016 ) . Reply to R.F. Sweis et al . Journal of Clinical Oncology vol. 35 , ( 2 ) 261 - 262 .

Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG et al. ( 2016 ) . 309TiP METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC) . Annals of Oncology . vol. 27 ,

Lenihan C, Cavicchioli F, O’Leary K, Shia A, Schmid P ( 2016 ) . Abstract 2110: The role of VAV-interacting Kruppel-like factor (VIK) in resistance to palbociclib in estrogen receptor-positive breast cancer . Cancer Research . vol. 76 , 2110 - 2110 .

Bouchekioua-Bouzaghou K, Lenihan C, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P ( 2016 ) . Abstract 2819: Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib . Cancer Research . vol. 76 , 2819 - 2819 .

Komulainen E, Shia A, Bansal J, Cavicchioli F, O’Leary K, Foster J, Schmid P ( 2016 ) . Abstract 3759: Inhibition of heat shock protein 27 (Hsp27) expression by apatorsen as a therapeutic strategy in breast cancer . Cancer Research . vol. 76 , 3759 - 3759 .

Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P ( 2016 ) . Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study . Clinical Breast Cancer vol. 16 , ( 6 ) 514 - 519 .

Schmid P, Wheatley DA, Thompson AM, Roy P, Bundred NJ, Purushotham AD, McIntosh S, Kummel S et al. ( 2016 ) . ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 34 ,

Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T et al. ( 2016 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . Journal of Clinical Oncology . vol. 34 , 11506 - 11506 .

Cortes J, Martinez Janez N, Sablin M-P, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart M-P et al. ( 2016 ) . Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results . Journal of Clinical Oncology . vol. 34 , 530 - 530 .

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK et al. ( 2016 ) . Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant . Nature Communications vol. 7 , ( 1 )

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B et al. ( 2016 ) . Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial . The Lancet Oncology vol. 17 , ( 6 ) 811 - 821 .

Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K et al. ( 2016 ) . 192TiP NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC . Journal of Thoracic Oncology vol. 11 , ( 4 ) s140 - s141 .

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2016 ) . Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer . Journal of Clinical Oncology vol. 34 , ( 17 ) 1987 - 1994 .

Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E ( 2016 ) . Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) . Cancer Research . vol. 76 ,

Schmid P, Ferreira M, Dubey S, Zaiss M, Harper-Wynne C, Makris A, Brown V, Kristeleit H et al. ( 2016 ) . Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer . Cancer Research . vol. 76 ,

Schmid P, Wheatley D, Baird R, Chan S, Abraham J, Tutt A, Kristeleit H, Patel G et al. ( 2016 ) . Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603) . Cancer Research . vol. 76 ,

Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izquierdo1 P, Cutillas P, Schmid P ( 2016 ) . Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer . Cancer Research . vol. 76 ,

Hampsch R, Shee K, Miller T ( 2016 ) . Abstract P5-03-01: Therapeutic targeting of Rac GTPases in ER+ and HER2+ breast cancer . Cancer Research . vol. 76 ,

Schmid P, Pinder S, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R et al. ( 2016 ) . Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study) . Cancer Research . vol. 76 ,

Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) . Cancer Research . vol. 76 ,

Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) . CANCER RESEARCH . vol. 76 ,

Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L et al. ( 2016 ) . Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? . The Breast vol. 26 , 149 - 150 .

Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F et al. ( 2016 ) . Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study . Open Forum Infectious Diseases vol. 3 , ( 1 )

Sun NCJ, Shapshak P, Lachant NA, Hsu M-Y, Sieger L, Schmid P, Beall G, Imagawa DT ( 2016 ) . Bone Marrow Examination in Patients with AIDS and AIDS-Related Complex (ARC): Morphologic and In Situ Hybridization Studies . American Journal of Clinical Pathology vol. 92 , ( 5 ) 589 - 594 .

Mok T, Schmid P, de CGJ, Syrigos K, Martin C, Yamamoto N, Aren O, Arrieta O et al. ( 2016 ) . Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 27 ,

Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. ( 2016 ) . IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC . ANNALS OF ONCOLOGY . vol. 27 ,

Cortes J, Martinez Janesz N, Sablin MP, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart MP et al. ( 2016 ) . Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part . EUROPEAN JOURNAL OF CANCER . vol. 57 , S112 - S112 .

Ma BBY, Rudin CM, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor VM et al. ( 2016 ) . Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC . ANNALS OF ONCOLOGY . vol. 27 ,

Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. ( 2015 ) . 480TiP Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE . Annals of Oncology vol. 26 ,

Pacey S, Spicer JF, Chan PY, Hategan M, Repana D, Steele JP, Schmid P, Cook GJR et al. ( 2015 ) . Abstract B23: A phase 1 study in patients with mesothelioma or non small cell lung tumours requiring arginine to assess ADI-PEG 20 with pemetrexed and cisplatin (TRAP study) . Molecular Cancer Therapeutics . vol. 14 , b23 - b23 .

O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer vol. 113 , ( 6 ) 970 - 978 .

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K et al. ( 2015 ) . A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice . Molecular Neurodegeneration vol. 10 , ( 1 )

Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel EE, Chaft J et al. ( 2015 ) . 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes . European Journal of Cancer . vol. 51 ,

O’Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer vol. 113 , ( 6 ) 970 - 978 .

Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D ( 2015 ) . Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression . Journal of Neuroimmunology vol. 287 , 88 - 92 .

Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR et al. ( 2015 ) . Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer . Annals of Oncology vol. 26 , ( 9 ) 1904 - 1910 .

Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. ( 2015 ) . Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) tps8111 - tps8111 .

Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. ( 2015 ) . Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC) . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) 8028 - 8028 .

Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. ( 2015 ) . Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer . Journal of Clinical Oncology . vol. 33 , tps2612 - tps2612 .

Castan JC, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . 13P Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) . Annals of Oncology vol. 26 ,

Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S et al. ( 2015 ) . Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results . Cancer Research . vol. 75 ,

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2015 ) . Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study) . Cancer Research . vol. 75 ,

Zhang M, Martinelli F, Wu J, Schmid PJ, Quadrio M ( 2015 ) . Modal and non-modal stability analysis of electrohydrodynamic flow with and without cross-flow . Journal of Fluid Mechanics vol. 770 , 319 - 349 .

Andreoli A, Ruf MT, Itin P, Pluschke G, Schmid P ( 2015 ) . Phosphorylation of the ribosomal protein S6, a marker of mTOR (mammalian target of rapamycin) pathway activation, is strongly increased in hypertrophic scars and keloids . British Journal of Dermatology vol. 172 , ( 5 ) 1415 - 1417 .

Schmid P, Muthukumar D, Blackhall F, Lester J, Khan S, Illsley MC, Adams J, Baijal S et al. ( 2015 ) . Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar™ Trial . JOURNAL OF THORACIC ONCOLOGY vol. 10 , ( 9 ) S664 - S664 .

Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. ( 2015 ) . Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,

Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. ( 2015 ) . Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,

Possinger K, Regierer AC, Dieing A, Engelhardt D, Eucker J, Flath B, Folprecht G, Geißler M et al. ( 2015 ) . Herausgeber- und Autorenverzeichnis . Facharzt Hämatologie Onkologie , Elsevier

Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. ( 2015 ) . Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 26 , 147 - 147 .

Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC) . ANNALS OF ONCOLOGY . vol. 26 ,

Ruf MT, Andreoli A, Itin P, Pluschke G, Schmid P ( 2014 ) . Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis . British Journal of Dermatology vol. 171 , ( 6 ) 1533 - 1536 .

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes‐Williams V, Liang TJ et al. ( 2014 ) . Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling . Hepatology vol. 60 , ( 6 ) 1902 - 1910 .

Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R et al. ( 2014 ) . Effects of Hiking at Moderate and Low Altitude on Cardiovascular Parameters in Male Patients With Metabolic Syndrome: Austrian Moderate Altitude Study . Wilderness and Environmental Medicine vol. 25 , ( 3 ) 329 - 334 .

Meisenberg C, Ward SE, Schmid P, El-Khamisy SF ( 2014 ) . TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan . J Cancer Sci Ther vol. 6 , ( 7 ) 258 - 267 .

Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P ( 2014 ) . A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer . BMC Medicine vol. 12 , ( 1 )

Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2014 ) . Praxisleitlinien Ergometrie . Atemwegs- und Lungenkrankheiten vol. 40 , ( 06 ) 223 - 244 .

Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME et al. ( 2014 ) . A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer . Journal of Clinical Oncology . vol. 32 , tps1144 - tps1144 .

Heller T, Rotman Y, Koh C, Clark S, Haynes‐Williams V, Chang R, McBurney R, Schmid P et al. ( 2014 ) . Long‐term therapy of chronic delta hepatitis with peginterferon alfa . Alimentary Pharmacology & Therapeutics vol. 40 , ( 1 ) 93 - 104 .

Schmid P, Possinger K ( 2014 ) . Adjuvante und neoadjuvante systemische Therapie des Mammakarzinoms . Der Internist vol. 43 , ( 3 ) 341 - 353 .

Andreoli A, Ruf M-T, Sopoh GE, Schmid P, Pluschke G ( 2014 ) . Immunohistochemical Monitoring of Wound Healing in Antibiotic Treated Buruli Ulcer Patients . PLOS Neglected Tropical Diseases vol. 8 , ( 4 )

Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löβner C, Jung S, Böhm G et al. ( 2014 ) . Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets . PLOS ONE vol. 9 , ( 3 )

Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N et al. ( 2014 ) . A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer . ANNALS OF ONCOLOGY vol. 25 , ( 2 ) 505 - 511 .

Dizdarevic S, McCready R, Turner JFC, Bagley MC, Blower P, Schmid P, Flux G, Hall A et al. ( 2014 ) . Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41 , ( 6 ) 1255 - 1256 .

Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P ( 2013 ) . Abstract P2-09-05: The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes . Cancer Research vol. 73 , ( 24_Supplement )

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al. ( 2013 ) . Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer . Breast Cancer Research vol. 15 , ( 5 )

Young D, Mayer F, Vidotto N, Schweizer T, Berth R, Abramowski D, Shimshek DR, van der Putten PH et al. ( 2013 ) . Mutant Huntingtin Gene-Dose Impacts on Aggregate Deposition, DARPP32 Expression and Neuroinflammation in HdhQ150 Mice . PLOS ONE vol. 8 , ( 9 )

Paganetti P, Reichwald J, Bleckmann D, Abramowski D, Ammaturo D, Barske C, Danner S, Molinari M et al. ( 2013 ) . Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice . Neurobiology of Aging vol. 34 , ( 12 ) 2866 - 2878 .

Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A et al. ( 2013 ) . A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer . Breast Cancer Research and Treatment vol. 140 , ( 1 ) 73 - 82 .

Cope S, Ouwens MJNM, Jansen JP, Schmid P ( 2013 ) . Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models . Value in Health vol. 16 , ( 2 ) 403 - 417 .

Eder B, Hofmann P, Hödl R, Wonisch M, Schmid P, Pokan R ( 2013 ) . Cardiac rehabilitation effective in elderly patients? . Journal fur Kardiologie vol. 20 , ( 9-10 ) 262 - 268 .

Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson AM, Lackner M, Jones LJ et al. ( 2013 ) . Sensitivity to glutamine deprivation is dependent on the interplay between epigenetic regulation of Glutamine synthetase (Glul) and induction of autophagy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S141 - S141 .

Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson A, Lackner M, Lo NC et al. ( 2012 ) . Abstract P4-06-10: Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy . Cancer Research . vol. 72 ,

Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Leibundgut EO et al. ( 2012 ) . Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) . Lung Cancer vol. 78 , ( 3 ) 239 - 244 .

Aad G, Abajyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC . Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 716 , ( 1 ) 1 - 29 .

Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M et al. ( 2012 ) . Fragments of HdhQ150 Mutant Huntingtin Form a Soluble Oligomer Pool That Declines with Aggregate Deposition upon Aging . PLOS ONE vol. 7 , ( 9 )

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D et al. ( 2012 ) . The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma . British Journal of Cancer vol. 107 , ( 8 ) 1423 - 1432 .

Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. ( 2012 ) . 1660P Epigenetic Silencing of Arginino-Succinate Synthase (ASS1) Defines Arginine Depletion Therapy as a Novel Treatment Strategy for Breast Cancer . Annals of Oncology vol. 23 , ix532 - ix533 .

O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. ( 2012 ) . 169O Identification of Endoglin (CD105) as an Epigenetically Regulated Candidate Tumour Suppressor Gene in Lung Cancer . Annals of Oncology vol. 23 , ix73 - ix74 .

Wonisch M, Marko C, Niebauer J, Pokan R, Schmid P, Wiesinger E ( 2012 ) . Bedeutung des Krafttrainings zur Prävention und Rehabilitation internistischer Erkrankungen . Wiener klinische Wochenschrift vol. 124 , ( 9-10 ) 326 - 333 .

Herzig MC, Bidinosti M, Schweizer T, Hafner T, Stemmelen C, Weiss A, Danner S, Vidotto N et al. ( 2012 ) . High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain . PLOS ONE vol. 7 , ( 5 )

Chaperon F, Fendt M, Kelly PH, Lingenhoehl K, Mosbacher J, Olpe H-R, Schmid P, Sturchler C et al. ( 2012 ) . Gastrin-Releasing Peptide Signaling Plays a Limited and Subtle Role in Amygdala Physiology and Aversive Memory . PLOS ONE vol. 7 , ( 4 )

Shimshek DR, Schweizer T, Schmid P, van der Putten PH ( 2012 ) . Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1 . Scientific Reports vol. 2 , ( 1 )

Berent R, von Duvillard SP, Crouse SF, Auer J, Green JS, Niebauer J, Sinzinger H, Schmid P ( 2012 ) . Discontinuation of combined resistance–endurance training increases cardiovascular risk factors . International Journal of Cardiology vol. 156 , ( 2 ) 229 - 231 .

Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider . SCIENCE vol. 338 , ( 6114 ) 1576 - 1582 .

Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. ( 2012 ) . EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER . ANNALS OF ONCOLOGY . vol. 23 , 532 - 533 .

O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. ( 2012 ) . IDENTIFICATION OF ENDOGLIN (CD105) AS AN EPIGENETICALLY REGULATED CANDIDATE TUMOUR SUPPRESSOR GENE IN LUNG CANCER . ANNALS OF ONCOLOGY . vol. 23 , 73 - 74 .

Berent R, Auer J, von Duvillard SP, Sinzinger H, Schmid P ( 2011 ) . Komplikationen bei der Ergometrie . Herz vol. 35 , ( 4 ) 267 - 272 .

Nigro CL, Syed N, Lattanzio L, Dasoula A, Papoudou-Bai A, Schmid P, Merlano M, Hatzimichael E et al. ( 2011 ) . 1037 POSTER The Prolyl-3-hydroxylases (P3H) and P3H-related Genes CRTAP and SC65 Are Novel Transcriptionally Silenced Genes in Burkitt's Lymphoma . European Journal of Cancer . vol. 47 ,

Berent R, von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P ( 2011 ) . Resistance Training Dose Response in Combined Endurance-Resistance Training in Patients With Cardiovascular Disease: A Randomized Trial . Archives of Physical Medicine and Rehabilitation vol. 92 , ( 10 ) 1527 - 1533 .

Blohmer J-U, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R et al. ( 2011 ) . Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study . Journal of Clinical Oncology vol. 29 , ( 28 ) 3791 - 3797 .

Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ et al. ( 2011 ) . LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice . Human Molecular Genetics vol. 20 , ( 21 ) 4209 - 4223 .

Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran F-A et al. ( 2011 ) . Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes . Anticancer Research vol. 31 , ( 8 ) 2617 - 2622 .

Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, Schmid P, Blohmer J-U et al. ( 2011 ) . Prognostic significance of angiogenic factors in uterine cervical cancer . Anticancer Research vol. 31 , ( 8 ) 2589 - 2595 .

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC et al. ( 2011 ) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials . The Lancet vol. 378 , ( 9793 ) 771 - 784 .

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M et al. ( 2011 ) . High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials . Journal of Clinical Oncology vol. 29 , ( 24 ) 3224 - 3231 .

Berent R, Auer J, Franklin B, Schmid P, von Duvillard SP ( 2011 ) . Platelet Response to Aspirin 50 and 100 mg in Patients With Coronary Heart Disease Over a Five-Year Period . The American Journal of Cardiology vol. 108 , ( 5 ) 644 - 650 .

Lo Nigro C, Lattanzio L, Monteverde M, Syed N, Thompson AM, Garrone O, Cavicchioli F, Tonissi F et al. ( 2011 ) . The frequency of methylation of the NT5E gene in metastatic breast cancer . Journal of Clinical Oncology . vol. 29 , e11553 - e11553 .

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al. ( 2011 ) . Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer . Cancer Res vol. 71 , ( 9 ) 3317 - 3327 .

Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H ( 2011 ) . Detection of early atherosclerotic lesions in the carotid artery: Experimental and preliminary human data . International Journal of Angiology vol. 6 , ( 1 ) 24 - 29 .

Kritz H, Schmid P, Karanikas G, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 2011 ) . Passive smoking increases platelet thromboxane . International Journal of Angiology vol. 5 , ( 3 ) 134 - 139 .

White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P ( 2011 ) . Characterisation of transient benign hCG elevations in women following chemotherapy for GTT . Journal of Obstetrics and Gynaecology vol. 31 , ( 2 ) 169 - 172 .

SCHMID-ARAYA J, Figueroa Hernandez D, Schmid PE, Drouot C ( 2011 ) . Algivory in food webs of three temperate Andean rivers . Austral Ecology

Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, Lang IM, Marko C et al. ( 2011 ) . Practical implementation of guidelines for lipid lowering . Journal fur Kardiologie vol. 18 , ( 3-4 ) 96 - 99 .

Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons . EUR PHYS J C vol. 70 , ( 3 ) 755 - 785 .

Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Readiness of the ATLAS liquid argon calorimeter for LHC collisions . EUR PHYS J C vol. 70 , ( 3 ) 723 - 753 .

Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N et al. ( 2010 ) . Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast . JNCI Monographs vol. 2010 , ( 41 ) 162 - 177 .

Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H ( 2010 ) . Prickly pear changes ¹¹¹indium?LDL and ¹¹¹indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia . Journal of the Professional Association for Cactus Development vol. 12 , 67 - 79 .

Blackhall FH, O'Brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N ( 2010 ) . A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer . Journal of Thoracic Oncology vol. 5 , ( 8 ) 1285 - 1288 .

Schmid P, Fleischmann C, Wischnewsky M, Syed N, Shah R, Quinlan P, Tooth L, Kuemmel S et al. ( 2010 ) . Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer . Journal of Clinical Oncology . vol. 28 , 592 - 592 .

Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D ( 2010 ) . Association of IL-6, Hypothalamus-Pituitary-Adrenal Axis Function, and Depression in Patients With Cancer . Integrative Cancer Therapies vol. 9 , ( 3 ) 270 - 275 .

Collaboration A, Aad G, Abat E, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O et al. ( 2010 ) . Charged-particle multiplicities in pp interactions at s=900 GeV measured with the ATLAS detector at the LHC . Physics Letters B vol. 688 , ( 1 ) 21 - 42 .

Schmid PE, Schmid-Araya JM ( 2010 ) . Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream . FUND APPL LIMNOL vol. 176 , ( 4 ) 365 - 375 .

McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ ( 2010 ) . The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1 . British Journal of Cancer vol. 102 , ( 5 ) 810 - 814 .

Berent R, Auer J, Schmid P, Krennmair G, Crouse SF, Green JS, Sinzinger H, von Duvillard SP ( 2010 ) . Periodontal and coronary heart disease in patients undergoing coronary angiography . Metabolism vol. 60 , ( 1 ) 127 - 133 .

Blohmer J-U, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G et al. ( 2010 ) . Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial . Annals of Oncology vol. 21 , ( 7 ) 1430 - 1435 .

Berent R, Auer J, von Duvillard S, Sinzinger H, Steinbrenner D, Schmid P ( 2010 ) . Acute myocardial infarction with ST segment elevation in inferior and anterior leads: right ventricular infarction . BMJ Case Reports vol. 2010 , ( feb02 1 )

Lo Nigro C, Syed N, Lattanzio L, Dasoula A, Monteverde M, Hatzimichael E, Papoudou-Bai A, Schmid P et al. ( 2010 ) . P3H COLLAGEN PROLYL HYDROXYLASES ARE TISSUE SELECTIVE TUMOUR SUPPRESSORS . ANNALS OF ONCOLOGY . vol. 21 , 42 - 43 .

Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2009 ) . The ATLAS Collaboration . Nuclear Physics A . vol. 830 , 925c - 940c .

Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H et al. ( 2009 ) . Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors . Annals of Oncology vol. 21 , ( 3 ) 633 - 639 .

Berent R, von Duvillard SP, Crouse SF, Auer J, Green JS, Sinzinger H, Schmid P ( 2009 ) . Short-term residential cardiac rehabilitation reduces B-type natriuretic peptide . European Journal of Preventive Cardiology vol. 16 , ( 5 ) 603 - 608 .

Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al. ( 2009 ) . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer . Int J Cancer vol. 125 , ( 6 ) 1454 - 1463 .

Berent R, von Duvillard SP, Auer J, Sinzinger H, Schmid P ( 2009 ) . Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors . European Journal of Preventive Cardiology vol. 17 , ( 3 ) 296 - 302 .

Schmid PC, Kirchhoff HW ( 2009 ) . Zur Differentialdiagnose paramediastinaler Verschattungen des rechten Oberlappens und der Pleuritis mediastinalis superior (Fortschr. Röntgenstr. 81, 5:629, 1954) . RöFo vol. 82 , ( 05 ) 637 - 641 .

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ et al. ( 2009 ) . Third consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 20 , ( 11 ) 1771 - 1785 .

Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, Lindsay I, Wells M et al. ( 2009 ) . Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study . The Lancet vol. 374 , ( 9683 ) 48 - 55 .

van Ulsen P, Kuhn K, Prinz T, Legner H, Schmid P, Baumann C, Tommassen J ( 2009 ) . Identification of proteins of Neisseria meningitidis induced under iron‐limiting conditions using the isobaric tandem mass tag (TMT) labeling approach . Proteomics vol. 9 , ( 7 ) 1771 - 1781 .

Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer J-U, Sehouli J et al. ( 2009 ) . Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer . Anticancer Research vol. 29 , ( 2 ) 641 - 645 .

Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T et al. ( 2008 ) . Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial . Cancer Chemotherapy and Pharmacology vol. 64 , ( 2 ) 401 - 406 .

Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2008 ) . Practice guidelines for exercise testing . Journal fur Kardiologie vol. 15 , ( SUPPL. A ) 3 - 17 .

Kummel S, Eggemann H, Lueftner D, Gebauer N, Buehler H, Schaller G, Schmid P, Kreienberg R et al. ( 2008 ) . Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes . The International Journal of Biological Markers vol. 22 , ( 3 ) 186 - 193 .

Harvey RA, Pursglove HD, Schmid P, Savage PM, Mitchell HDC, Seckl MJ ( 2008 ) . Human chorionic gonadotropin free beta-subunit measurement as a marker of placental site trophoblastic tumors . The Journal of Reproductive Medicine vol. 53 , ( 8 ) 643 - 648 .

Lim AKP, Patel D, Patel N, Hawtin K, Dayal L, Schmid P, Savage P, Seckl MJ ( 2008 ) . Pelvic imaging in gestational trophoblastic neoplasia . The Journal of Reproductive Medicine vol. 53 , ( 8 ) 575 - 578 .

Aad G, Abat E, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi BA, Abolins M et al. ( 2008 ) . The ATLAS Experiment at the CERN Large Hadron Collider . J INSTRUM vol. 3 , Article S08003 ,

Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ ( 2008 ) . Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE) . Annals of Oncology vol. 19 , ( 9 ) 1578 - 1583 .

Schmid PA, Burger HR, Linke RP, Bühler H ( 2008 ) . Morbus Whipple mit reaktiver (AA-)Amyloidose . DMW - Deutsche Medizinische Wochenschrift vol. 118 , ( 33 ) 1188 - 1192 .

Schmid PA, Burger HR, Spycher MA, Bühler H, Heitz PU ( 2008 ) . Primäre Amyloidose der Leber . DMW - Deutsche Medizinische Wochenschrift vol. 117 , ( 26 ) 1014 - 1018 .

Hauner H, Schmid P, Pfeiffer E ( 2008 ) . Differential Effect of Insulin on the Synthesis of Lipoprotein Lipase and Glycerophosphate Dehydrogenase Activity in Developing Rat Adipocyte Precursor Cells . Hormone and Metabolic Research vol. 18 , ( 10 ) 719 - 721 .

TONG MJ, HWANG S, LEFKOWITZ M, LEE S, CO RL, CONRAD A, SCHMID P, LO K ( 2008 ) . Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin . Journal of Gastroenterology and Hepatology vol. 9 , ( 6 ) 587 - 591 .

Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, Evison J, Tarr P et al. ( 2008 ) . Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006 . HIV Medicine vol. 9 , ( 3 ) 142 - 150 .

Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J et al. ( 2008 ) . A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines . Annals of Oncology vol. 19 , ( 5 ) 871 - 876 .

Schmid P, Seckl MJ ( 2008 ) . Gestational trophoblastic tumours . Treatment of Cancer, Fifth Edition ,

Syed N, Coley H, Sehouli J, Koensgen D, Mustea A, Slozarek P, McNeish I, Schmid P et al. ( 2008 ) . Methylation reversal reveals Snk/PLK2 as a critical determinant of clinical outcome in ovarian cancer . CANCER RESEARCH . vol. 68 ,

Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, Pluschke G ( 2007 ) . Development of Highly Organized Lymphoid Structures in Buruli Ulcer Lesions after Treatment with Rifampicin and Streptomycin . PLOS Neglected Tropical Diseases vol. 1 , ( 1 )

Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn H-J ( 2007 ) . Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy . Cancer Chemotherapy and Pharmacology vol. 61 , ( 2 ) 347 - 348 .

Gish RG, Lau DT-Y, Schmid P, Perrillo R ( 2007 ) . A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B . The American Journal of Gastroenterology vol. 102 , ( 12 )

Schmid P ( 2007 ) . Bisphosphonate zur Behandlung tumorinduzierter Knochenveränderungen . Die Onkologie vol. 13 , ( 7 ) 609 - 618 .

Schmid P ( 2007 ) . Hochdosischemotherapie beim Mammakarzinom . Die Onkologie vol. 13 , ( 5 ) 409 - 424 .

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L et al. ( 2007 ) . Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study . Journal of Clinical Oncology vol. 25 , ( 18 ) 2509 - 2515 .

Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS et al. ( 2007 ) . Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93 . Annals of Oncology vol. 18 , ( 7 ) 1177 - 1184 .

Hofmann P, Pokan R, Duvillard SV, Schmid P ( 2007 ) . The Conconi Test . International Journal of Sports Medicine vol. 18 , ( 05 ) 397 - 398 .

Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . British Journal of Cancer vol. 96 , ( 5 ) 732 - 737 .

Kümmel S, Rezai, Kimmig R, Schmid P ( 2007 ) . Dose-dense chemotherapy for primary breast cancer . Current Opinion in Obstetrics & Gynecology vol. 19 , ( 1 ) 75 - 81 .

SHAPSHAK P, RESNICK L, OSBORNE MA, TOURTELLOTTE WW, SCHMID P, LEE M, RUBINSTEIN G, IMAGAWA DT et al. ( 2006 ) . HTLV‐III Can Cross the Blood‐Brain Barriera . Annals of the New York Academy of Sciences vol. 529 , ( 1 ) 291 - 294 .

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . British Journal of Cancer vol. 95 , ( 12 ) 1709 - 1709 .

Schmid P, Possinger K ( 2006 ) . Chemotherapie des metastasierten Mammakarzinoms . Geburtshilfe und Frauenheilkunde vol. 128 , ( 6 ) 318 - 326 .

Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Frank J et al. ( 2006 ) . Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia . The Journal of Reproductive Medicine . vol. 51 , 879 - 887 .

Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES et al. ( 2006 ) . Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment . Journal of Clinical Oncology vol. 24 , ( 30 ) 4862 - 4866 .

Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K et al. ( 2006 ) . Biomarkers of depression in cancer patients . Cancer vol. 107 , ( 11 ) 2723 - 2729 .

Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . British Journal of Cancer vol. 95 , ( 9 ) 1145 - 1147 .

Schmid P ( 2006 ) . Wirkungsweise und Einsatzmöglichkeiten . best practice onkologie vol. 1 , ( 1 ) 42 - 57 .

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J et al. ( 2006 ) . Second consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 18 , ( 2 ) 215 - 225 .

Pokan R, Hofmann P, von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M et al. ( 2006 ) . Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients . British Journal of Sports Medicine vol. 40 , ( 9 ) 773 - 778 .

Hoon DSB, Doi F, Giuliano AE, Schmid P, Conrad AJ, Noguchi S, Aihara T ( 2006 ) . The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase‐polymerase chain reaction . Cancer vol. 76 , ( 3 ) 533 - 535 .

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . Journal of Clinical Oncology vol. 24 , ( 18_suppl ) 5033 - 5033 .

Constam DB, Schmid P, Aguzzi A, Schachner M, Fontana A ( 2006 ) . Transient Production of TGF‐β2 by Postnatal Cerebellar Neurons and its Effect on Neuroblast Proliferation . European Journal of Neuroscience vol. 6 , ( 5 ) 766 - 778 .

Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G et al. ( 2006 ) . Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes . Anticancer Research . vol. 26 , 1719 - 1726 .

Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A ( 2006 ) . Chemotherapy treatment options for elderly women with breast cancer . Anticancer Research . vol. 26 , 1673 - 1676 .

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 24 , 263S - 263S .

Moll J, Eibel H, Schmid P, Sansig G, Botteri F, Palacios R, Van Der Putten H ( 2005 ) . Thymic hyperplasia in transgenic mice caused by immortal epithelial cells expressing c‐kit ligand . European Journal of Immunology vol. 22 , ( 6 ) 1587 - 1594 .

Schmid P, Flath B, Akrivakis K, Heilmann V, Mergenthaler H-G, Sezer O, Kreienberg R, Possinger K ( 2005 ) . Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study . Investigational New Drugs vol. 23 , ( 4 ) 349 - 356 .

Schmid P, Heilmann V, Schulz C-O, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K et al. ( 2005 ) . Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study . Journal of Cancer Research and Clinical Oncology vol. 131 , ( 9 ) 568 - 574 .

Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S et al. ( 2005 ) . Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial . Annals of Oncology vol. 16 , ( 10 ) 1624 - 1631 .

Schmid P, Cox D, Bilbe G, McMaster G, Morrison C, Stähelin H, Lüscher N, Seiler W ( 2005 ) . TGF‐βS and TGF‐β type II receptor in human epidermis: Differential expression in acute and chronic skin wounds . The Journal of Pathology vol. 171 , ( 3 ) 191 - 197 .

Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Gynakologische Praxis vol. 29 , ( 2 ) 351 - 358 .

Schmid P, Possinger K ( 2005 ) . Gemcitabine (Gemzar) . Internistische Praxis vol. 45 , ( 2 ) 415 - 422 .

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K et al. ( 2005 ) . Proteasome: an emerging target for cancer therapy . Anti-Cancer Drugs vol. 16 , ( 5 ) 475 - 481 .

Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Padiatrische Praxis vol. 66 , ( 3 ) 521 - 528 .

Stead TK, Schmid-Araya JM, Schmid PE, HILDREW AG ( 2005 ) . The distribution of body size in a stream community: one system, many patterns . Journal of Animal Ecology vol. 74 , ( 3 ) 475 - 487 .

Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Chirurgische Praxis vol. 64 , ( 2 ) 351 - 358 .

Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M et al. ( 2005 ) . Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial . Journal of Clinical Oncology vol. 23 , ( 3 ) 432 - 440 .

Schmid P, Krocker J, Schulz C-O, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer J-U et al. ( 2005 ) . Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial . Anti-Cancer Drugs vol. 16 , ( 1 ) 21 - 29 .

Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K ( 2005 ) . Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study . Investigational New Drugs vol. 23 , ( 2 ) 139 - 146 .

POKAN R, VON DUVILLARD SP, LUDWIG J, ROHRER A, HOFMANN P, WONISCH M, SMEKAL G, SCHMID P et al. ( 2004 ) . Effect of High-Volume and -Intensity Endurance Training in Heart Transplant Recipients . Medicine & Science in Sports & Exercise vol. 36 , ( 12 ) 2011 - 2016 .

Schmid P, Helmreich G, Gradauer L, Stowasser G, Bronnenmayer J, Pokan R ( 2004 ) . Are there non responders to exercise therapy after myocardial infarction? . Journal fur Kardiologie vol. 11 , ( 11 ) 453 - 457 .

Pokan R, Hofmann P, Wonisch M, Smekal G, Bachl N, Mayr K, Benzer W, Schmid P ( 2004 ) . Performance diagnostic and target training heart rate in cardiac rehabilitation . Journal fur Kardiologie vol. 11 , ( 11 ) 446 - 452 .

Untch* M, Kahlert* S, Kosse V, Bondar G, Kienle E, Maubach L, Hillger H, Schmid P et al. ( 2004 ) . Leuprorelinacetat als 3-Monats-Depot zeigt gleiche Wirksamkeit wie CMF in der adjuvanten Therapie prä- und perimenopausaler, nodal positiver Mammakarzinom-Patientinnen mit positivem Rezeptorstatus - Die TABLE-Studie . Geburtshilfe und Frauenheilkunde vol. 64 , ( 12 ) 1316 - 1323 .

Shapshak P, Tourtellotte WW, Wolman M, Verity N, Verity MA, Schmid P, Syndulko K, Bedows E et al. ( 2004 ) . Search for virus nucleic acid sequences in postmortem human brain tissue using in situ hybridization technology with cloned probes: Some solutions and results on progressive multifocal leukoencephalopathy and subacute sclerosing panencephalitis tissue . Journal of Neuroscience Research vol. 16 , ( 1 ) 281 - 301 .

Schmid P, Helmreich G, Gradauer L, Schmid F ( 2004 ) . Percutaneous transradial artery approach for coronary diagnostics and PCI . Journal fur Kardiologie vol. 11 , ( 9 ) 359 - 362 .

Höfer S, Benzer W, Brandt D, Laimer H, Schmid P, Bernardo A, Oldridge NB ( 2004 ) . MacNew Heart Disease Lebensqualitätsfragebogen nach Herzinfarkt: . Zeitschrift für Klinische Psychologie und Psychotherapie vol. 33 , ( 4 ) 270 - 280 .

Dieing A, Schulz C-O, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K ( 2004 ) . Orbital metastases in breast cancer: report of two cases and review of the literature . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 12 ) 745 - 748 .

Schmid P, Krocker J, Morack G, Heilmann V, Blohmer J-U, Michniewicz K, Köhler G, Schaller-Kranz T et al. ( 2004 ) . Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 11 ) 657 - 663 .

Pokan R, Wonisch M, Schmid P ( 2004 ) . Changes in the athlete's heart in the ECG . Internistische Praxis vol. 44 , ( 1 ) 79 - 88 .

Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P et al. ( 2003 ) . Long‐term therapy of chronic hepatitis B with lamivudine . Hepatology vol. 32 , ( 4 ) 828 - 834 .

Schmid P, Schmid F, Smekal G, Pokan R ( 2003 ) . Physical Activity and Primary Prevention . Journal fur Kardiologie vol. 10 , ( 12 ) 548 - 553 .

Beslija S, Bonneterre J, Burstein HJ, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W et al. ( 2003 ) . Consensus on medical treatment of metastatic breast cancer . Breast Cancer Research and Treatment . vol. 81 ,

Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K ( 2003 ) . Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients . Breast Cancer Research and Treatment vol. 80 , ( 3 ) 245 - 255 .

Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O ( 2003 ) . Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer . British Journal of Cancer vol. 88 , ( 9 ) 1406 - 1410 .

Schmid P, Possinger K ( 2003 ) . Bisphosphonates in Metastatic Breast Cancer . Breast Cancer Research and Treatment . vol. 81 , 87 - 93 .

Schmid P, Possinger K ( 2003 ) . Which Treatment When? . Breast Cancer Research and Treatment . vol. 81 , 9 - 10 .

Osborne CS, Schmid P ( 2003 ) . Epidermal–dermal interactions regulate gelatinase activity in Apligraf®, a tissue‐engineered human skin equivalent . British Journal of Dermatology vol. 146 , ( 1 ) 26 - 31 .

Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hörtnagl H, Gunga H-C, Klingler A, Fries D et al. ( 2002 ) . Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome . European Journal of Applied Physiology vol. 88 , ( 6 ) 506 - 514 .

Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L et al. ( 2002 ) . Characterization of nuclease‐resistant ribozymes directed against hepatitis B virus RNA* . Journal of Viral Hepatitis vol. 9 , ( 6 ) 411 - 418 .

Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K ( 2002 ) . Prediction of Response to Hormonal Treatment in Metastatic Breast Cancer . Oncology vol. 63 , ( 4 ) 309 - 316 .

Schmid P, Possinger K ( 2002 ) . Hochdosischemotherapie beim Mammakarzinom . Medizinische Klinik vol. 97 , ( 11 ) 677 - 686 .

Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler H-G, Huhn D et al. ( 2002 ) . The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas . Anti-Cancer Drugs vol. 13 , ( 9 ) 907 - 913 .

Schmid P, Possinger K ( 2002 ) . High-Dose Chemotherapy in High-Risk Primary Breast Cancer . Oncology Research and Treatment vol. 25 , ( 2 ) 112 - 120 .

Schmid P, Possinger K ( 2002 ) . Systemtherapie beim Mammakarzinom - Adjuvante und neoadjuvante Therapie: Aktueller Stand, aktuelle Studien . Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie vol. 37 , ( 2 ) 137 - 149 .

Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL ( 2002 ) . Patients co‐infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA . Journal of Viral Hepatitis vol. 6 , ( 3 ) 203 - 208 .

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E et al. ( 2002 ) . Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate) . Anticancer Research vol. 22 , ( 4 ) 2325 - 2332 .

Schmid P, Possinger K ( 2002 ) . Interactions of antioestrogens and aromatase inhibitors . Forum (Genoa, Italy) vol. 12 , ( 1 ) 45 - 59 .

Pokan R, Hofmann P, Smekal G, Wonisch M, Bachl N, Schmid P ( 2002 ) . Performance testing for regulating training in exercise therapy of cardiovascular disease . Internistische Praxis vol. 42 , ( 4 ) 797 - 806 .

Blatt, Mutchnick, Tong, Klion, Lebovics, Freilich, Bach, Smith et al. ( 2001 ) . Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States . Journal of Viral Hepatitis vol. 7 , ( 3 ) 196 - 202 .

Schmid P, Sezer O, Possinger K ( 2001 ) . Bisphosphonate in der Onkologie: Tatsächlicher Nutzen oder nur kein Schaden? . Pharmazie in unserer Zeit vol. 30 , ( 6 ) 519 - 528 .

Schmid PE, Schmid-Araya JM ( 2001 ) . Editorial: Eine kritische Betrachtung zum Stand der Ökologischen Forschung . Environmental Sciences Europe vol. 13 , ( 5 ) 255 - 257 .

Schmid P, Possinger K ( 2001 ) . Liposomal anthracyclines for improved cardiac tolerability . The Breast vol. 10 , 22 - 27 .

Schmid P, Fritz J, Possinger K ( 2001 ) . Treatment options for metastatic breast cancer . Internistische Praxis vol. 41 , ( 2 ) 319 - 332 .

Sinzinger H, Hoppichler F, Kritz H, Laimer H, Schmid P, Silberbauer K, Toplak H ( 2001 ) . HDL-2000: A consensus. HDL--a neglected lipoprotein . Wiener klinische Wochenschrift vol. 113 , ( 5-6 ) 212 - 214 .

Schmid P, Osborne C, Cox DA, Grenet O, Medina J, Chibout S-D ( 2001 ) . An Intrinsic Antibiotic Mechanism in Wounds and Tissue-Engineered Skin . Journal of Investigative Dermatology vol. 116 , ( 3 ) 471 - 472 .

Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K ( 2001 ) . Achievement of Complete Remission in Refractory Hodgkin's Disease with Prolonged Infusion of Gemcitabine . Investigational New Drugs vol. 19 , ( 1 ) 101 - 104 .

Grosse Y, Schmid P, Possinger K ( 2001 ) . Bisphosphonates in the treatment of breast cancer. Prevention and adjuvant therapy . Tagliche Praxis vol. 42 , ( 4 ) 727 - 734 .

Pokan R, Pelikan J, Retzer H, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Fruhwald FM et al. ( 2001 ) . Leistungsfähigkeit und herzfrequenz von patienten mit KHK im MAXLASS und deren zusammenhang mit dem herzfrequenzverhalten und der myokardialen funktion unter belastung im stufentest . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )

Schmid P ( 2001 ) . Stellenwert der Bewegungstherapie in der Primär- und Sekundärprävention der KHK . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )

Lueftner DI, Schmid P, Kienle E, Possinger K ( 2001 ) . Upregulation of Her-2/neu under chemical castration: Serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer . Breast Cancer Research and Treatment vol. 69 , ( 3 )

Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, Schmid P, Gasparini F et al. ( 2001 ) . mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia . Neuropharmacology vol. 40 , ( 1 ) 10 - 19 .

Schmid P ( 2000 ) . Immunohistologic Characterization of Graftskin (Apligraf®) . Wounds vol. 12 , ( 5 SUPPL. A )

Sezer O, Eucker J, Jakob C, Schmid P, Possinger K ( 2000 ) . Prolonged infusion of gemcitabine in refractory hodgkin's disease . Blood vol. 96 , ( 11 PART II )

POKAN R, VON DUVILLARD SP, HOFMANN P, SMEKAL G, FRUHWALD FM, GASSER R, TSCHAN H, BARON R et al. ( 2000 ) . Change in left atrial and ventricular dimensions during and immediately after exercise . Medicine & Science in Sports & Exercise vol. 32 , ( 10 ) 1713 - 1718 .

Sezer O, Langelotz C, Blohmer J-U, Schmid P, Akrivakis K, Possinger K ( 2000 ) . Detection of HMGI-C in the peripheral blood of breast cancer patients . European Journal of Cancer vol. 36 , ( 15 ) 1944 - 1948 .

Possinger K, Schmid P ( 2000 ) . Therapeutische Möglichkeiten beim Mammakarzinom . Die Onkologie . vol. 6 , s2 - s4 .

Schmid PE, Tokeshi M, Schmid-Araya JM ( 2000 ) . Relation Between Population Density and Body Size in Stream Communities . Science vol. 289 , ( 5484 ) 1557 - 1560 .

Schmid P, Possinger K ( 2000 ) . New therapeutic approaches in advanced breast carcinoma. Palliative measures are increasingly more tolerable . MMW - Fortschritte der Medizin vol. 142 , ( 35 ) 22 - 24 .

Sinzinger H, Chehne F, Schmid P, Kritz H ( 2000 ) . Unaltered homocysteine levels during simvastatin therapy . Wiener klinische Wochenschrift vol. 112 , ( 12 ) 540 - 543 .

Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Stuschke M, Schweigert M, Siebert G et al. ( 2000 ) . Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy . Journal of Cancer Research and Clinical Oncology vol. 126 , ( 6 ) 352 - 356 .

Possinger K, Schmid P ( 2000 ) . Neue Substanzen zur Therapie des Mammakarzinoms . Die Onkologie vol. 6 , ( 5 ) 392 - 409 .

Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E ( 2000 ) . Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance . Berliner und Münchener tierärztliche Wochenschrift vol. 113 , ( 7-8 ) 299 - 305 .

Sezer O, Eucker J, Schmid P, Possinger K ( 2000 ) . New therapeutic approaches in primary systemic AL amyloidosis . Annals of Hematology vol. 79 , ( 1 ) 1 - 6 .

Sezer O, Schmid P, Mergenthaler H-G, Beinert T, Possinger K ( 1999 ) . Use of Bisphosphonates in Therapy and Prophylaxis of Cancer-Induced Bone Diseases . Oncology Research and Treatment vol. 22 , ( 5 ) 400 - 404 .

Schmid P, Tong M, Conrad A, McHutchison J, Blatt LM ( 1999 ) . Analysis of the viability of freezer stored serum samples for hepatitis C virus RNA analysis by the SUPERQUANT® method: results of a 16 year retrospective study . Journal of Virological Methods vol. 82 , ( 2 ) 201 - 206 .

Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler H-G, Possinger K ( 1999 ) . Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia . Annals of Hematology vol. 78 , ( 10 ) 475 - 477 .

Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler H-G, Possinger K ( 1999 ) . Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer . Anti-Cancer Drugs vol. 10 , ( 7 ) 625 - 632 .

Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler H-G, Possinger K ( 1999 ) . Prolonged infusion of gemcitabine in stage IV breast cancer . Anti-Cancer Drugs vol. 10 , ( 6 ) 525 - 532 .

Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, Schmid P, Gerosa S et al. ( 1999 ) . Detection of de novo Hepatitis C Virus Infection by Polymerase Chain Reaction in Hemodialysis Patients . American Journal of Nephrology vol. 19 , ( 3 ) 383 - 388 .

Schmid P, Itin P, Cox D ( 1999 ) . Proteolytic inactivation of transforming growth factor beta3 by elastase in venous leg ulcers: implications for clinical trials using topically-applied peptide growth factors . British Journal of Dermatology vol. 140 , ( 6 ) 1170 - 1172 .

POKAN R, HOFMANN P, VON DUVILLARD SP, SMEKAL G, HÖGLER R, TSCHAN H, BARON R, SCHMID P et al. ( 1999 ) . The heart rate turn point reliability and methodological aspects . Medicine & Science in Sports & Exercise vol. 31 , ( 6 ) 903 - 907 .

Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H et al. ( 1999 ) . Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support . Bone Marrow Transplantation vol. 23 , ( 9 ) 967 - 969 .

Sinzinger H, Schmid P, O'Grady J ( 1999 ) . Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment . Atherosclerosis vol. 143 , ( 2 ) 459 - 460 .

Helmreich G, Gradauer L, Schmid P ( 1999 ) . Duration and complications in diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 545 - 549 .

Schmid P, Helmreich G, Gradauer L ( 1999 ) . Methods for diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 538 - 542 .

Hoon DSB, Sarantou T, Doi F, D.J. D, Kuo C, Conrad AJ, Schmid P, Turner R et al. ( 1998 ) . Detection of metastatic breast cancer by β‐hCG polymerase chain reaction . International Journal of Cancer vol. 69 , ( 5 ) 369 - 374 .

Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC ( 1998 ) . Testicular germ cell tumors in patients with human immunodeficiency virus infection . Cancer vol. 77 , ( 10 ) 2109 - 2116 .

POKAN R, HOFMANN P, VON DUVILLARD SP, BEAUFORT F, SMEKAL G, GASSER R, KLEIN W, EBER B et al. ( 1998 ) . The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction . Medicine & Science in Sports & Exercise vol. 30 , ( 10 ) 1475 - 1480 .

McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A ( 1998 ) . Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chonic HCV infection? . Journal of Hepatology vol. 29 , ( 3 ) 362 - 368 .

Blatt LM, Tong MJ, McHutchison JG, Russell J, Schmid P, Conrad A ( 1998 ) . Discordance Between Serum Alanine Aminotransferase (ALT) and Virologic Response to IFN-β2b in Chronic Hepatitis C Patients with High and Low Pretreatment Serum Hepatitis C Virus RNA Titers . Journal of Interferon & Cytokine Research vol. 18 , ( 2 ) 75 - 80 .

Schmid P, Itin P, Cherry G, Bi C, Cox DA ( 1998 ) . Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar . American Journal Of Pathology vol. 152 , ( 2 ) 485 - 493 .

ROCHUS P, PETER H, P. VDS, MARTIN S, ROBERT G, ROBERT Z, M. FF, BERND E et al. ( 1998 ) . Parasympathetic receptor blockade and the heart rate performance curve . Medicine & Science in Sports & Exercise vol. 30 , ( 2 ) 229 - 233 .

Diamantis ID, Kouroumalis E, Koulentaki M, Fasler-Kan E, Schmid PA, Hirsch HH, Bühler H, Gyr K et al. ( 1997 ) . Influence of hepatitis G virus infection on liver disease . European Journal of Clinical Microbiology & Infectious Diseases vol. 16 , ( 12 ) 916 - 919 .

Lau D, Everhart J, Kleiner D, Park Y, Vergalla J, Schmid P, Hoofnagle J ( 1997 ) . Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa . Gastroenterology vol. 113 , ( 5 ) 1660 - 1667 .

ROCHUS P, PETER H, P. VDS, FRIEDRICH B, MARTIN S, M. FF, ROBERT Z, BERND E et al. ( 1997 ) . Left ventricular function in response to the transition from aerobic to anaerobic metabolism . Medicine & Science in Sports & Exercise vol. 29 , ( 8 ) 1040 - 1047 .

Sanders VJ, Felisan SL, Waddell AE, Conrad AJ, Schmid P, Swartz BE, Kaufman M, Walsh GO et al. ( 1997 ) . Presence of Herpes Simplex DNA in Surgical Tissue From Human Epileptic Seizure Foci Detected by Polymerase Chain Reaction: Preliminary Study . JAMA Neurology vol. 54 , ( 8 ) 954 - 960 .

Kupferschmidt H, Schwery S, Schmid PA, Bühler H ( 1997 ) . Bile duct cysts in adults . Swiss Medical Weekly vol. 127 , ( 26 ) 1117 - 1123 .

Hofmann P, Pokan R, Bachl N, Schmid P ( 1997 ) . A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31-4) . The Journal of Sports Medicine and Physical Fitness vol. 37 , ( 2 ) 151 - 155 .

O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H ( 1997 ) . EFFECT OF ISRADIPINE ON IN-VIVO PLATELET FUNCTION . Thrombosis Research vol. 86 , ( 5 ) 363 - 371 .

PETER H, ROCHUS P, P. VDS, J. SF, ROBERT Z, PETER S ( 1997 ) . Heart rate performance curve during incremental cycle ergometer exercise in healthy young male subjects . Medicine & Science in Sports & Exercise vol. 29 , ( 6 ) 762 - 768 .

Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DS ( 1997 ) . Melanoma-associated antigens as messenger RNA detection markers for melanoma . Cancer Research vol. 57 , ( 7 ) 1371 - 1376 .

Schmid PA, Schwery S, Kupferschmidt H, Bühler H ( 1996 ) . The absence of autoantibodies does not rule out autoimmune hepatitis . Swiss Medical Weekly . vol. 126 , 2090 - 2093 .

Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA ( 1996 ) . Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan . Proceedings of the National Academy of Sciences of the United States of America vol. 93 , ( 18 ) 9710 - 9715 .

Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R et al. ( 1996 ) . Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer . European Journal of Cancer vol. 32 , ( 10 ) 1712 - 1718 .

SCHMID P, ITIN P, RUFLI T ( 1996 ) . In situ analysis of transforming growth factors-β(TGF-β1, TGG-β2, TGF-β3) and TGF–β type II receptor expression in basal cell carcinomas . British Journal of Dermatology vol. 134 , ( 6 ) 1044 - 1051 .

Benzer W, Schmid P, Maehr G, Drexel H ( 1996 ) . Effects of intravenous magnesium chloride reverses left ventricular end-diastolic pressure in coronary artery disease . The American Journal of Cardiology vol. 77 , ( 8 ) 638 - 640 .

Sinzinger H, Virgolini I, Kritz H, Schmid P, Rogatti W ( 1996 ) . Prostaglandin E1 increases binding of 123I-low-density lipoprotein to the human liver in vivo . European Journal of Clinical Pharmacology vol. 49 , ( 6 ) 515 - 520 .

Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 1996 ) . Passive smoking and platelet thromboxane . Thrombosis Research vol. 81 , ( 4 ) 451 - 460 .

Schmid P, Cox D, Itin P ( 1996 ) . Enhanced expression of TGF-β and TGF-β receptors (Type I and type II) in normal granulation tissue and hypertrophic scars . Dermatology . vol. 193 , 164 - 165 .

Schmid P, Mathys T, Rufli T, Itin PH ( 1996 ) . Expression of TGF-β and TGF-β receptors (Type I and type II in verruca vulgaris) - An in situ hybridization and immunohistorchemical analysis . Dermatology . vol. 193 ,

Moll J, Schmid P, Sansig G, Van Der Putten H ( 1996 ) . The pattern of prothymosinα gene expression coincides with that ofmyc proto-oncogenes during mouse embryogenesis . Journal of Molecular Histology vol. 28 , ( 1 ) 45 - 52 .

Kritz H, Schmid P, Keiler A, O'Grady J, Sinzinger H ( 1995 ) . Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished . Thrombosis Research vol. 80 , ( 6 ) 483 - 489 .

Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagra RM, Russell JJ, Tourtellotte WW ( 1995 ) . Quantifying HIV-1 RNA Using the Polymerase Chain Reaction on Cerebrospinal Fluid and Serum of Seropositive Individuals With and Without Neurologic Abnormalities . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 10 , ( 4 ) 425 - 435 .

Kritz H, Schmid P, Sinzinger H ( 1995 ) . Passive Smoking and Cardiovascular Risk . JAMA Internal Medicine vol. 155 , ( 18 ) 1942 - 1948 .

Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ et al. ( 1995 ) . Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay . Journal of Clinical Oncology vol. 13 , ( 8 ) 2109 - 2116 .

Schmid P, Itin P, Rufli T ( 1995 ) . In situ analysis of transforming growth factor-βs (TGF-β1, TGF-β2, TGF-β3and TGF-3 type II receptor expression in malignant melanoma . Carcinogenesis vol. 16 , ( 7 ) 1499 - 1503 .

Pokan R, Hofmann P, Lehmann M, Leitner H, Eber B, Gasser R, Schwaberger G, Schmid P et al. ( 1995 ) . Heart rate deflection related to lactate performance curve and plasma catecholamine response during incremental cycle ergometer exercise . European Journal of Applied Physiology vol. 70 , ( 2 ) 175 - 179 .

Benzer W, Schmid P ( 1995 ) . Rehabilitation after myocardial infarct--a multidisciplinary responsibility . Wiener klinische Wochenschrift vol. 107 , ( 24 )

van Hille B, Richener H, Schmid P, Puettner I, Green JR, Bilbe G ( 1994 ) . Heterogeneity of vacuolar H+-ATPase: differential expression of two human subunit B isoforms . Biochemical Journal vol. 303 , ( 1 ) 191 - 198 .

Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA ( 1994 ) . The Type I Interferon System Is Locally Activated in Psoriatic Lesions . Journal of Interferon & Cytokine Research vol. 14 , ( 5 ) 229 - 234 .

Schmid P, Conrad A, Syndulko K, Singer EJ, Handley D, Li X, Tao G, Fahy-Chandon B et al. ( 1994 ) . Quantifying HIV-1 proviral DNA using the polymerase chain reaction on cerebrospinal fluid and blood of seropositive individuals with and without neurologic abnormalities . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 7 , ( 8 ) 777 - 788 .

Schmid P, Cox D, Vanderputten H, Mcmaster GK, Bilbe G ( 1994 ) . Expression of TGF-βS and TGF-β Type II Receptor mRNAs in Mouse Folliculogenesis: Stored Maternal TGF-β2 Message in Oocytes . Biochemical and Biophysical Research Communications vol. 201 , ( 2 ) 649 - 656 .

Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar B ( 1994 ) . Sleep disturbance and appetite loss after lovastatin . The Lancet vol. 343 , ( 8903 )

Singer EJ, Syndulko K, Fahy-Chandon B, Schmid P, Conrad A, Tourtellotte WW ( 1994 ) . Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 7 , ( 3 ) 265 - 271 .

Syndulko K, Singer EJ, Nogales-Gaete J, Conrad A, Schmid P, Tourtellotte WW ( 1994 ) . Laboratory Evaluations in HIV-1-Associated Cognitive/Motor Complex . Psychiatric Clinics of North America vol. 17 , ( 1 ) 91 - 123 .

Singer EJ, Syndulko K, Fahy-Chandon BN, Shapshak P, Resnick L, Schmid P, Conrad AJ, Tourtellotte WW ( 1994 ) . Cerebrospinal fluid p24 antigen levels and intrathecal immunoglobulin G synthesis are associated with cognitive disease severity in HIV-1 . AIDS vol. 8 , ( 2 ) 197 - 204 .

Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H ( 1994 ) . Influence of calcium antagonists on platelet function and vascular prostacyclin production . Blood Pressure . vol. 1 , 75 - 80 .

Pirich C, Fitscha P, Schmid P, Sinzinger H ( 1994 ) . Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall . Blood Pressure . vol. 1 , 70 - 74 .

Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H ( 1994 ) . Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humans . Blood Pressure . vol. 1 , 65 - 69 .

Mansuy IM, van der Putten H, Schmid P, Meins M, Botteri FM, Monard D ( 1993 ) . Variable and multiple expression of Protease Nexin-1 during mouse organogenesis and nervous system development . Development vol. 119 , ( 4 ) 1119 - 1134 .

Linke RP ( 1993 ) . The classification of protein storage diseases . DMW - Deutsche Medizinische Wochenschrift vol. 118 , ( 38 ) 1382 - 1383 .

Schmid P, Cox D, McMaster GK, Itin P ( 1993 ) . In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis . Archives of Dermatological Research vol. 285 , ( 6 ) 334 - 340 .

Schmid P, Kunz S, Cerletti N, Mcmaster G, Cox D ( 1993 ) . Injury Induced Expression of TGF-β1 mRNA Is Enhanced by Exogenously Applied TGF-βS . Biochemical and Biophysical Research Communications vol. 194 , ( 1 ) 399 - 406 .

Sinzinger H, Schmid P, Pirich C, Virgolini I, Pesau B, Granegger S, O'Grady J ( 1992 ) . Treatment of hypercholesterolaemia in children . The Lancet vol. 340 , ( 8818 ) 548 - 549 .

Pirich C, Schmid P, Pidlich J, Sinzinger H ( 1992 ) . Lowering cholesterol with Anticholest--a high fiber guar-apple pectin drink . Wiener klinische Wochenschrift vol. 104 , ( 11 ) 314 - 316 .

Maier R, Schmid P, Cox D, Bilbe G, McMaster GK ( 1991 ) . Localization of transforming growth factor-β1, -β2 and -β3 gene expression in bovine mammary gland . Molecular and Cellular Endocrinology vol. 82 , ( 2-3 ) 191 - 198 .

Schmid P, Lorenz A, Hameister H, Montenarh M ( 1991 ) . Expression of p53 during mouse embryogenesis . Development vol. 113 , ( 3 ) 857 - 865 .

Hirning U, Schmid P, Schulz WA, Rettenberger G, Hameister H ( 1991 ) . A comparative analysis of N-myc and c-myc expression and cellular proliferation in mouse organogenesis . Cells and Development vol. 33 , ( 2 ) 119 - 125 .

Schmid P, Cox D, Bilbe G, Maier R, Mcmaster GK ( 1991 ) . Differential expression of TGF β1, β2 and β3 genes during mouse embryogenesis . Development vol. 111 , ( 1 ) 117 - 130 .

Schmid P, Schulz WA ( 1990 ) . Coexpression of the C-MYC protooncogene with α-fetoprotein and albumin in fetal mouse liver . Differentiation vol. 45 , ( 2 ) 96 - 102 .

Govindarajan S, Conrad A, Lim B, Valinluck B, Kim AM, Schmid P ( 1990 ) . Study of preneoplastic changes of liver cells by immunohistochemical and molecular hybridization techniques . Archives of Pathology & Laboratory Medicine vol. 114 , ( 10 ) 1042 - 1045 .

Shapshak P, Sun NC, Resnick L, Hsu MY, Tourtellotte WW, Schmid P, Conrad A, Fiala M et al. ( 1990 ) . The detection of HIV by in situ hybridization . Modern Pathology vol. 3 , ( 2 ) 146 - 153 .

Hirning U, Schmid P, Schulz WA, Kozak LP, Hameister H ( 1989 ) . In developing brown adipose tissue c-myc protooncogene expression is restricted to early differentiation stages . Cells and Development vol. 27 , ( 3 ) 243 - 248 .

Schmid P, Schulz WA, Hameister H ( 1989 ) . Dynamic Expression Pattern of the myc Protooncogene in Midgestation Mouse Embryos . Science vol. 243 , ( 4888 ) 226 - 229 .

Tourtellotte WW, Schmid P, Pick P, Verity N, Martinez S, Shapshak P ( 1987 ) . Quest for a reliable, valid, and sensitive in situ hybridization procedure to detect viral nucleic acids in the central nervous system . Neurochemical Research vol. 12 , ( 6 ) 565 - 571 .

HAUNER H, SCHMID P, PFEIFFER EF ( 1987 ) . Glucocorticoids and Insulin Promote the Differentiation of Human Adipocyte Precursor Cells into Fat Cells . The Journal of Clinical Endocrinology & Metabolism vol. 64 , ( 4 ) 832 - 835 .

Tourtellotte WW, Verity AN, Schmid P, Martinez S, Shapshak P ( 1987 ) . Covalent binding of formalin fixed paraffin embedded brain tissue sections to glass slides suitable for in situ hybridization . Journal of Virological Methods vol. 15 , ( 2 ) 87 - 99 .

Tourtellotte WW, Schmid P, Shapshak P ( 1987 ) . Advanced detection of viral nucleic acids in the central nervous system: a progress report . Nuova Rivista di Neurologia vol. 57 , ( 3 ) 163 - 165 .

Shapshak P, Tourtellotte WW, Nakamura S, Graves MC, Darvish M, Hoffman D, Walsh MJ, Fareed GC et al. ( 1985 ) . Subacute sclerosing panencephalitis: measles virus matrix protein nucleic acid sequences detected by in situ hybridization . Neurology vol. 35 , ( 11 ) 1605 - 1609 .

Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1978 ) . Analysis of nucleon structure functions in CERN bubble chamber neutrino experiments . Nuclear Physics B vol. 142 , ( 1-2 ) 1 - 28 .

Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1978 ) . Cross sections for neutrino and antineutrino neutral current interactions . Physics Letters B vol. 76 , ( 4 ) 505 - 511 .

Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Krenz W, Morfin J, Schmitz P et al. ( 1978 ) . Observation of prompt neutrinos from 400 Gev proton-nucleus collisions . Physics Letters B vol. 74 , ( 1-2 ) 143 - 147 .

Bosetti PC, Deden H, Fritze P, Grässler H, Hasert FJ, Kirch D, Morfin J, Seyfert H et al. ( 1978 ) . Di-Lepton events in the BEBC narrow-band beam neutrino experiment . Physics Letters B vol. 73 , ( 3 ) 380 - 384 .

Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1977 ) . Total cross sections for charged-current neutrino and antineutrino interactions in BEBC in the energy range 20–200 GeV . Physics Letters B vol. 70 , ( 2 ) 273 - 277 .

Collaboration A-B-B-C-C-H-W, Grässler H, Schmitz P, Seyfert HH, Böttcher H, Klabuhn J, Lanius K, Naumann T et al. ( 1977 ) . Production and decay of the Δ(970) and D(1285) mesons in π±p interactions at 16 GeV/c . Nuclear Physics B vol. 121 , ( 2 ) 189 - 209 .

Collaboration A-B-B-C-C-H-W, Deutschmann M, Honecker R, Kirk H, Klein M, Nahnhauer R, Hartmann R, Plothow H et al. ( 1976 ) . Determination of the fire-ball dimensions from second-order interference between two pions . Nuclear Physics B vol. 103 , ( 2 ) 198 - 212 .

Collaboration A-B-C-L-V, Lauscher P, Otter G, Wieczorek H, Matthäus E, Schreiber HJ, Cocconi VT, Counihan MJ et al. ( 1975 ) . Spin-parity structure of the (Kπ) system produced in the reaction K−p → (K−π+)n . Nuclear Physics B vol. 86 , ( 2 ) 189 - 200 .

Herring H, Schmid P, Savill M ( 1957 ) . Beggars on Golden Stools. Report on Latin America . Hispanic American Historical Review vol. 37 , ( 2 )